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Abstract
Cancer remains one of the largest pandemics in the world, with millions affected by
this disease every year. Since the discovery of the anticancer properties of cisplatin
and other platinum-based drugs, metal-based chemotherapies have been extensively
researched. Due to the high levels of toxicity of many platinum-based drugs, a rise
in research using other metal-based drugs for the treatment of cancer has been ob-
served. Of these, platinum group metals such as ruthenium, rhodium and iridium have
shown great promise over the last several decades. RAPTA-type (ruthenium arene
1,3,5-triaza-7-phosphaadamantane) complexes have shown great promise in vivo for
the treatment of certain cancers. Combining RAPTA with other biologically active
groups has often resulted in increased potency and selectivity against various cancer
cells in vitro. In this study, we investigated the synthesis, characterisation and biolog-
ical evaluation of salicylaldimine complexes with an alkylated PTA scaffold. All of the
metal complexes were screened for their activity against MCF7 breast cancer cells in
vitro, in addition, the most active complexes were screened against Chinese Hamster
Ovarian (CHO) non-cancerous cells to evaluate their selectivity.
A series of salicylaldimine ligands, as well as a benzyl alkylated PTA scaffold were
prepared. Complexes of these ligands were synthesised by a reaction with [RuCl(µ-
Cl)(p-cymene)]2, [RhCl(µ-Cl)(Cp*)]2 or [IrCl(µ-Cl)(Cp*)]2. In addition to this, new
PTA containing analogues of these neutral complexes were also prepared by react-
ing the afore mentioned salicylaldimine complexes with the alkylated PTA scaffold.
All the compounds were characterised using an array of techniques including NMR
spectroscopy, IR spectroscopy and mass spectrometry. Single crystal X-ray diffraction
(XRD) was used to confirm the bidentate coordination mode of the salicylaldimine
ligand to the metal centre, as well as the presence of the metal-phosphorus bond for
the alkylated PTA complexes.
All of the metal complexes were evaluated against the MCF7 breast cancer cell line.
The ruthenium and iridium salicylaldimine complexes showed comparable or greater
cytotoxicity than cisplatin at 20 µM against the MCF7 cancer cells, as well as greater
iv
cytotoxicity than their rhodium counterparts. Three of the salicylaldimine complexes
exhibited potent activity (18 < IC50 < 21 µM). Selectivity studies showed that two
of these complexes had a greater affinity for cancerous cells than for the CHO non-
cancerous cells. All of the alkylated PTA complexes were less cytotoxic than cisplatin
against the MCF7 cancer cells. Preliminary mechanistic studies of the most active
complexes suggest ruthenium undergoes solvation prior to 5′-GMP binding, whereas
iridium was inert to the solvation process.
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Stringer, S. Prince, A. T. Hutton and G. S. Smith - Synthesis and Biological
Evaluation of PGM Complexes Based on Derivatised PTA Scaffolds.
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Chapter 1
Advances in the Use of Platinum
Group Metals as Anticancer Agents
1.1 Introduction
1.1.1 Cancer Mortality
There are several strategies to optimise the therapeutic properties of medicinal com-
pounds, with great emphasis on directing compounds to specific sites, lowering of
healthy cellular cytotoxicity and overcoming resistance pathways.1 The latter is essen-
tial for maintaining the longevity of the drug. Non-infectious diseases often exploit
essential biological processes making them hard to target and difficult to treat. Can-
cers are a group of non-infectious diseases which are characterised and defined by their
uncontrolled cell division.2 This pandemic affects approximately 600 000 people a year
in South Africa alone.3,4 Of this number, approximately 7% of those diagnosed results
in mortality. Since cancer is a major cause of death worldwide, it is important to
understand its biology for effective drug design.
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1.1.2 What is Cancer?
Benign tumours (tumours that are confined within tissue boundaries5) are often the
easiest cancers to treat as the growth is localised. Proteases secreted from the cells often
fracture the tissue boundary and pervade the adjoining cells.5 Once this has occurred,
platelets crowd the cell and often gets destroyed by immune cells, which sees a drop in
the platelet count. For those cells not destroyed by the immune cells, the cancer cells
can spread throughout the body by the lymphatic or bloodstream systems and settle in
another locale (secondary site, Figure 1.1).6 At this new locale the process can continue
and spread to even more locations. This process is referred to as metastasis (Figure 1.1).
This process can be delayed or prevented by tumour dormancy, poor vascularisation,
apoptosis (programmed cell death), immune responses or induced treatments.7,8
Figure 1.1: A diagram depicting the process of metastasis.6
1.1.3 Chemotherapy and Setbacks
Advances in the treatment of these diseases have improved dramatically over the last
century.8 Chemotherapy, the use of natural or synthetic chemicals for the treatment of
diseases, is the most common treatment of cancer.9 Often chemotherapies have negative
side effects like chemotherapy-induced-nausea-vomiting (CINV),8 caused by the non-
2
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selective nature of many chemotherapeutic agents towards cancerous cells or oncogenes.
These drugs often prevent imperative biological processes, leading to deleterious effects,
such as hair loss and mild arthritis.10
To improve the efficacy of chemotherapeutics, researchers have identified suitable bi-
ological targets for drugs.5 High concentrations of cancer inducing and suppressing
proteins (e.g. Ras and Myc) have been found in cancerous cells,5,11,12 making them
favourable targets for selective activity. These targets have been a main focus when
developing chemotherapeutics over the last few decades. Since many therapies ex-
hibit several short-comings, the need for suitable alternatives is dire. Metal-based
compounds have generated interest in recent years as a suitable alternative class of
compounds. In the subsequent sections, some advances of metal-based compounds
towards the treatment of cancer are discussed.
1.2 Platinum-containing Complexes
The discovery of the anticancer properties of cisplatin (1.1, Figure 1.2) by Rosen-
berg13,14 has paved the way for the research of metal-based treatments for this disease.
Based on mechanistic studies, it was concluded that cisplatin undergoes hydrolysis to
form a diaqua cationic complex (1.2, Figure 1.2) which facilitates intermembrane trans-
fer. The aqua complex 1.2 interacts with DNA by binding to two adjacent guanine-N7
nitrogen donor atoms (1.3, Figure 1.2), which leads to cell apoptosis.15 Further mech-
anistic studies revealed that hydrolysis was not the only possible ligand substitution
that could occur. The soft acidic nature of platinum meant it could bind to sulphur
containing ligands, such as methionine and glutathione (1.4, Figure 1.2), which also
facilitates cell membrane transfer and cell apoptosis.16 Cisplatin is the most frequently
used and effective metal-based anticancer drug against ovarian and testicular cancers,
however the lack of selectivity towards cancerous cells often leads to negative side
effects.8,17
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Figure 1.2: The proposed mechanism of action of cisplatin.16
Analogues of cisplatin have also been synthesised and biologically evaluated. The idea
was to replace the chloride or/and primary amines with more labile ligands to increase
the rate of aquation of the complex to increase the efficiency of DNA binding, and
to increase selectivity towards cancerous cells.16 A few analogues have been proven
to be effective against various cancer types. Carboplatin (1.5, Figure 1.3) is a sec-
ond generation derivative of cisplatin with a cyclobutane-carboxylate replacing the
chlorido ligands. It has been found to have lower cytotoxicity against healthy cells
relative to cisplatin; however higher dosages are required due to lower reactivity.18 Ox-
aliplatin (1.6, Figure 1.3) is a third generation derivative of cisplatin, which has both
the chlorido and ammino groups replaced by more labile groups, but maintaining the
cis nature of the ligands. It is mostly used in the treatment of colorectal cancer,19
the third most frequently diagnosed cancer reported in 2012 worldwide.20 Although
both of these agents are currently used in chemotherapy, they have limitations. One
such limitation is that certain tumours are prone to drug resistance, which subdues
the effects of the prescribed treatments.21 Further development of drugs that possess
activity against cancerous cells, as well drugs that are able to overcome resistance, is
obligatory to treat cancer.21
4
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Figure 1.3: Cisplatin derivatives, carboplatin (1.5) and oxaliplatin (1.6)
Due to the efficacy of the afore-mentioned drugs, other platinum complexes have been
synthesised and evaluated for their anticancer properties. In addition to this, inter-
actions between DNA and platinum complexes were investigated. Barauah et al.22
investigated the cytotoxicity and DNA binding mechanisms of acridine-thiourea plat-
inum complexes, where acridine could be used as a DNA intercalating agent. The
acridine-thiourea ligands and complexes (1.7 and 1.8, Figure 1.4) were found to be cy-
totoxic against HL-60 leukemia, 2008 (cisplatin sensitive) and C13 (cisplatin resistant)
human ovarian cancer cell lines, with 1.7 being highly active in micromolar concen-
trations. Against the HL-60 leukaemia cancer cell line, it was found that there was
approximately a 85-fold difference in activity between 1.7 and 1.8. DNA binding stud-
ies suggested that 1.8 exclusively intercalates with DNA, while 1.7 strongly bound to
DNA via two binding manifolds: intercalating and Pt-DNA binding, suggesting that
cell apoptosis is strongly linked to the strength of the interactions between the complex
and biomolecules.22
Figure 1.4: Acridinylthiourea complexes that exhibit anticancer activity.22
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In light of the success of mononuclear platinum-based complexes, a polynuclear deriva-
tive of cisplatin with naturally occurring polyamines was investigated with partial
success. BBR3464 (1.9, Figure 1.5) is a trinuclear platinum complex that has shown
significant activity against cisplatin-sensitive and cisplatin-resistant cell lines.23 The
addition of the polyamine scaffold increased cell membrane permeability, with a differ-
ent mechanism of action towards the unwinding of double stranded DNA. BBR3464
has undergone Phase II clinical trials, identifying it as a potential drug candidate, but
was ultimately excluded due to the low selectivity towards cancer cells.24
Figure 1.5: Structure of BBR3464 (1.9).23
Platinum-based treatments are still currently used today despite high levels of toxicity
towards non-tumour cells. The low selectivity of platinum towards cancer cell DNA
over healthy cells and the development of drug resistance has paved the way for the
investigation of other platinum group metals (PGMs) in drugs for the treatment of
cancer.
1.3 Palladium-containing Complexes
Palladium complexes are closely related to platinum complexes as the two metals share
similar coordination chemistry.25 Mono- and multinuclear palladium complexes have
been evaluated against various cancer cell lines to determine the potency of the metal.25
Complexes bearing structural similarities to cisplatin exhibited near identical activity
against various cell lines.25,26 In a study by Ulukaya and co-workers, palladium com-
plexes with an (N, N, N)-tridendate ligand exhibited potent anti-growth, anti-invasive
and apoptosis inducing activity both in vitro and in vivo.27 In recent years cyclopal-
ladated complexes have shown to be highly active against HeLa, HT-29, K562 and
6
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MDA-MB-468 cancer cell lines, with the complexes showing greater activity than cis-
platin.28 Increased activity was observed in the dimeric complexes.
Smith and co-workers investigated the effect of palladium thiosemicarbozone complexes
(1.10, Figure 1.6) against several cancer cell line families of WHCO, KYSE, CaSki and
HeLA.29 Thiosemicarbozones are robust, multidentate ligands which has shown both
anticancer and antibacterial properties. The complexes showed moderate anticancer
activity and were found to be less active than the free ligand. Further analysis showed,
against the HeLa cell line, that these palladium complexes were apoptosis inducers.
Cyclometallalated palladium complexes (1.11, Figure 1.6), investigated by Navarro-
Ranninger et al. were evaluated against the triple negative MDA-MB-468 breast cancer
cell line and HL-60 human cancer cells.30 Platinum analogues of these complexes were
also evaluated as a comparison of the anticancer activity between the two metals.
The palladium complexes were observed to have a lower anticancer activity than the
platinum analogues. It was found that palladium did not bind to DNA like platinum,
which could attribute to the lower anticancer activity observed. This lack of binding
suggests that palladium will not disturb DNA-dependent processes in healthy cells.
Figure 1.6: General structures of the complexes investigated by Smith et al. (1.10)29
and Navarro-Ranninger et al. (1.11).30
Very few mechanistic studies has been done in order to understand the underlying
reason for the activity of palladium complexes but these complexes do show great
potential as anticancer agents.
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1.4 Ruthenium-containing Complexes
Despite that the afore-mentioned metals and others, such as gold and copper31 that dis-
play anticancer properties; ruthenium complexes have shown to be the most promising.
The first ruthenium complex to show anticancer activity was cis-dichlorotetraammineru-
thenium chloride (1.12, Figure 1.7), a cisplatin derivative with a ruthenium metal
centre.31 A few years later, cis-[RuCl2(DMSO)4] was shown to be active against both
primary and metastatic tumours, which has paved the way for ruthenium-based com-
plexes as anticancer treatments (1.13, Figure 1.7).31
Figure 1.7: The first ruthenium complexes to show anticancer activity.
Some ruthenium(III) complexes are classified as prodrugs, as they are biologically
inert.31 These complexes can reduce to ruthenium(II) complexes, which is widely re-
garded as the active species.32 These prodrugs are generally inactive against primary
tumours, but have been found to be highly active towards preventing the development
of tumours.31,32 New Anti-tumour Metastasis Inhibitor-A (NAMI-A, 1.14, Figure 1.8)
successfully completed Phase I clinical trials. It was shown to interact with matrix
metalloproteinases, which prevented tumour growth.33 NAMI-A was found to be most
effective in lung tissues, as it has the highest collagen content, to which NAMI-A
binds strongly.33 Similar ruthenium(III) complexes, such as KP1019 (1.15, Figure 1.8)
and (N)KP1339 (1.16, Figure 1.8), have been shown to induce apoptosis and are cur-
rently in clinical trials.33,34 Even though these compounds have shown activity towards
metastases, their lack of activity towards primary tumours resulted in the research of
ruthenium-based compounds which are active towards both metastases and primary
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tumours. NAMI-A, KP1019 and (N)KP1339 all undergo a complete exchange of lig-
ands under physiological conditions, which led researchers to believe that the more
stable ruthenium(II) complexes are responsible for the anticancer properties.33 One of
the first ruthenium(II) complexes to be used as a framework was developed by Sadler
et al., i.e. the ruthenium arene ethylenediammine (RAED) framework (Figure 1.9).35
Derivatives of this framework showed good in vitro (comparable to carboplatin) and in
vivo activity.35 The cytotoxicity of these complexes were largely due to the rapid aqua-
tion and DNA affinity, which is similar to cisplatin’s mechanism of action. To increase
the lipophilicity of the cationic RAED complexes, extended arenes were incorporated,
which resulted in greater pipurene-piarene stacking and greater DNA binding affinity.
36
Figure 1.8: Ruthenium compounds that have shown promising biological activity.
Figure 1.9: Ruthenium Arene Ethylene Diammine (RAED) complex synthesised by
Sadler et al.35
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Bipyridyl ligands are known to intercalate with DNA to disrupt its replication. Glazer
et al. investigated ruthenium(II) complexes incorporating bipyiridyl ligands,37 as these
groups are light-activated, which could give insight into the anticancer properties of the
ligands attached. Complexes 1.18 and 1.19 (Figure 1.10) exhibited very low anticancer
activity against HL60, A549 and A549 spheroid cancer cells when tested in a dark room.
Potent anticancer activity was observed when the assay was performed in conditions
with light. This suggests that the activity of these complexes are largely due to an
electronic transfer aided by a light source. In the light assay, complexes were found
to exhibit anticancer activity superior to that of cisplatin. Agarose gel electrophoresis
indicated a lack of any DNA interaction under dark conditions, but with light both
DNA photocleavage and photobinding were responsible for the anticancer activity.
Figure 1.10: Bipyridyl complexes investigated by Glazer et al.37
Another strategy exploited to aid with toxicity and anticancer activity is to bind met-
als to biologically significant ligands before treating cancer cells. Incorporating amino
acids as part of metal complexes has been proven to be a favourable strategy for im-
proved selectivity. Lima and co-workers used this approach and treated sarcoma-180
tumour cells (S180) with ruthenium(II) amino acid complexes.38 Ruthenium bipyridyl
moieties were complexed with various amino acids to treat sarcoma-180 cancer and
L929 normal cell lines to evaluate the biological activity and selectivity. These com-
plexes were more cytotoxic than cisplatin against the S180 cancers but were found to
be less toxic against L929. This suggests that these types of complexes are highly
selective for cancer cells over normal cells. This claim was further supported with an
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increase in caspases proteins (a family of cystine proteinases which are responsible for
apoptosis) and an increase in mitochondrial dysfunction levels upon treatment with
the complex. Due to the success of this strategy, many other non-cancer systems are
being treated using the same strategy.39
The success of ruthenium complexes in vitro and in vivo, strategies used to overcome
detrimental pathways and the rise in resistance strains probed the use of other metals
using the same approaches.
1.5 Osmium-containing Complexes
Analogous to ruthenium, osmium piano-stool complexes have been investigated with
some success. Osmium complexes have shown promise as protein-DNA binding in-
hibitors which are strongly associated with the progression of human cancers. An
osmium(II) complex with a chlorophenazine bipyridyl ligand showed promise in the
inhibition of DNA and tyrosine kinase product (signal transducer and transcription
proteins, STAT) binding.40 These STAT families are essential for the development of
cancers and inflammation. A strong binding of the complex to STAT5B (has a role
in apoptosis) was observed while a weak bond was observed for the cancer causing
STAT5A.
Osmium derivatives of NAMI-A and the Keppler series (Figure 1.8) were synthesised
and evaluated for their anticancer properties. The osmium complexes were signifi-
cantly more active than the ruthenium analogues when tested against the HT-29 and
SK-BR-3 cancer cell lines.41 The inert nature of these complexes showed that hydrol-
ysis is not essential for the activity, as observed with the ruthenium analogues. These
complexes can be used as models to study biodistribution of unhydrolysed NAMI-A
type complexes. The Keppler series analogues possessing osmium(II) and osmium(IV)
oxidation states were tested in vivo using a Hep3B SCID mouse model and were well
tolerated with good activities observed. In contrast, the ruthenium analogues of the
azolium salts showed weaker cytotoxicity than the osmium counterparts. The authors
11
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reasoned this to the cellular uptake of the complexes.41–43 Osmium(IV) complexes have
been investigated as potential anticancer agents against various cancer cell lines. Ex-
ceptional cytotoxicity of osmium(IV) bipyridyl complexes were reported by Lippard
et al.44 These complexes were observed to have two separate pathways that inhibit
cell growth, namely the p53 dependant and p53 independent pathways. Similar to the
ruthenium analogues of the complexes investigated, the ligand system determines the
apoptosis pathway.
Even though osmium complexes do show a great deal of promise, the high levels of
normal cell toxicity is not favourable for use of some of these compounds as biological
agents.
1.6 Rhodium-containing Complexes
The success of ruthenium(II) complexes as potential anticancer agents has led re-
searchers to take interest in the isoelectronic metal centre, rhodium(III).45 The first
rhodium complex shown to exhibit anticancer properties was a dirhodium complex,
[Rh2(RC OO)2(S)2] (where S = coordinating solvent e.g. H2O). The use of carboxylato-
rhodium complexes as anticancer agents extends to more recent rhodium(II) citrate
complexes for the treatment of breast cancer.46 The kinetically inert rhodium(III)
centre can be made labile by using cyclopentadienyl (Cp) and pentamethylcyclopenta-
dienyl (Cp*) ligands.45 Due to its unique chemistry, rhodium(III) Cp* complexes often
show similar activity to that of their ruthenium arene counterparts.45 This relation has
sparked interest in using rhodium(III) complexes as potential anticancer agents.
Based on the success of imidazole-based ruthenium(III) complexes (1.14, Figure 1.8),
other metals have been investigated as anticancer agents. Mestroni et al. investigated
rhodium(III) imidazole-based complexes which are similar to the ruthenium(III) com-
plexes in Figure 1.8.47 The complexes were tested against A2780, A2780/cp8, LoVo
and Calu cells with cisplatin as the positive control. Complexes 1.20 and 1.21 (Fig-
ure 1.11) exhibited greater anticancer activity than cisplatin against the tested cell
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lines. Strong DNA interactions were observed for these complexes resulting in early
stage DNA termination during DNA synthesis. Unlike cisplatin or the ruthenium ana-
logues, no preferential binding of the rhodium complexes to guanine was observed. The
success of these complexes in vitro sparked research using nitrogen donor ligands with
rhodium centres.
Figure 1.11: Most active rhodium(III) imidazole-based complexes investigated by
Mestroni et al.47
A study has been conducted using rhodium Cp* picolinamide (N,N -chelating deriva-
tive of the natural occurring nicotinamide) complexes as potential anticancer agents
(1.22, Figure 1.12).48 Screening of the complex against the A2780 human ovarian cell
line revealed an IC50 value of 28.8 µM, significantly less active than the cisplatin stan-
dard.48 DNA interaction studies suggests binding of the complex in a similar manner
to cisplatin.48,49 A study using N,N -chelating ligands (1.23, Figure 1.12) showed im-
proved results to the picolinamide complex.50 The dipyridophenazine ligand was found
to intercalate between the base pairs of the DNA double helix, similar to the com-
plexes investigated by Baruah et al.22,50 Compound 1.23 and its derivatives exhibited
up to 70 fold greater activity than cisplatin against the MCF7 and HT-29 cell lines.
Fluorescence studies showed ∼ 88 % cell apoptosis, which was due to the generation of
reactive oxygen species (ROS) within the cell.50 A significant decrease in the activity
was observed when only the ligands were tested.
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Figure 1.12: General structures investigated by Almondares et al.48 (1.22) and Hack-
enberg et al.50 (1.23).
Ott et al.51 investigated the effects of different N -heterocyclic carbene complexes us-
ing rhodium(I) with 1,5-cyclooctadiene (COD) and carbon monoxide ligands, against
the MCF7 breast cancer cell line, HT-29 colon carcinoma and TrxR, a thioredoxin
reductase. These complexes exhibited great activity against the tested cell lines and
reductase with strong inhibition of the TrxR.51 Inhibition of the TrxR was independent
of the ligand but the rhodium centre was required to showcase the inhibition effect. A
stronger binding affinity to albumin and DNA was observed compared to cisplatin. Re-
duced rhodium uptake was observed when albumin was present, showing that rhodium
can bind to various biological entities. Rhodium clusters have shown to unpair DNA
base pairs to inhibit DNA synthesis. Carneiro et al.52 investigated the effects of cit-
rate ligands on the anticancer properties of rhodium(II) citrate clusters against MCF7
breast cancer cells. The anticancer activity was found to be low (IC50 > 200µM). At
higher concentrations, blebbing of cells were observed. Blebbing is a process of the
cytoskeleton breaking up due to stress, an indication of apoptosis. Due to the strong
interactions with DNA, these complexes were toxic to healthy cells as well.
1.7 Iridium-containing Complexes
A large number of organometallic complexes have been researched for their anticancer
properties; however there are very few iridium complexes that have been researched.
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Iridium(III) is commonly kinetically inert,31 and by coordinating strong field ligands
to the metal centre, it can be liberated to its more reactive d6 low spin state.31 Like
rhodium, Cp and Cp* ligands are responsible for the increased lability of the inert metal
centre.31 Compounds 1.24 and 1.25 were observed to have comparable cytoactivity
to that of cisplatin against the A2780 cell line, and ' 10-fold greater activity against
A2780cisR and MCF-7 cell lines.53 These iridium compounds were also observed to
accumulate more efficiently in the cancer cells in comparison to cisplatin; a desirable
property for anticancer agents. Changing the bipyridyl ligand to an azopyridyl group
increased activity by ∼ 1.5-2 fold (likely due to the lipophilic arene and the charge
aiding in hydrophilicity).54
Figure 1.13: Iridium Cp* complexes, 1.24 and 1.25 investigated for cell accumula-
tion.53
In a separate study by Kasparkova and workers, another N,N -chelating iridium complex
with a functionalised Cp* ring (1.26, Figure 1.14) was investigated for its apoptosis
inducing properties. It was found that the complex was cytoactive against various
cisplatin sensitive and resistant cell lines.55 It was found that 1.26 is amongst the
DNA damaging class of therapeutic compounds, and binds more effectively to DNA
than the other iridium complexes tested.55 Apoptosis was induced more by 1.26 than
cisplatin, with a concentration-dependant florescence - a definitive indication of ROS
formation.
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Figure 1.14: Iridium complex investigated for induced cell apoptosis.55
A study using multiple (N,N)- and (N,C)- pyridyl moieties to enhance activity was
investigated by Lu et al.56 These iridium complexes were found to be substitutionally
inert. The complexes showed strong inhibition against various cancer cell lines and
were found to be more active than the cisplatin standard.56 This strong inhibition is
most likely due to intercalation with DNA since the metal centre was found to be inert.
These complexes also showed potent inhibition activity against S. aureus, a common
bacterium responsible for skin disease in mammals. Meggers and co-workers investi-
gated the antiangiogenic properties of (N,N )-pyridocarbozole iridium COD complexes
against Flt-4.57 Complex 1.27 (Figure 1.15) showed high in vitro selectivity for the
Flt-4 kinase, nanomolar inhibition of the kinase and very low cytotoxicity in vivo.
This complex served as a scaffold for iridium(III) octahedral complexes as potential
anticancer agents. More recently, Mao and co-workers have used this concept by in-
corporating C-H activated ligands.58 The C-H activated complexes were tested against
HeLa, A549(S/R), MDA-MB-231, PC3 and LO2 cancer cell lines and were found to
be more active than the commercially used cisplatin - particularly in the A549-R as-
say where complexes were up to 180 times more active. This effect was also observed
for Payne and co-workers using C-H activated propylbenzylimine complexes.59 Mito-
Tracker Deep Red (MTDR) tests on 1.27 revealed that the complexes penetrate the cell
membrane via an energy-dependent mechanism, as opposed to an endocytic pathway.
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Figure 1.15: Most active iridium complex discussed in Meggers et al.57
1.8 RAPTA complexes
As shown in the previous sections, the ligand system plays a vital role in the cytotox-
icity of the complex. One of the more promising ligand systems, PTA (1,3,5-triaza-7-
phosphaadamantane), has been studied extensively.
Piano-stool complexes (1.28 and 1.29, Figure 1.16) such as ruthenium arene 1,3,5-
triaza-7-phosphaadamantane (RAPTA) complexes have shown potential as anticancer
agents. In the case of the RAPTA complexes, both lipophilic and hydrophilic entities
are present which is favourable for bio-availability.60 These complexes showed promise
in vivo.33 The low cytotoxicity against non-tumorous cells and selectively targeting
tumour cells via protein binding, provided the rationale for additional studies with
other metals.45 The most active primary RAPTA series is RAPTA-C (1.28 with R =
p-cymene, R1 = R2 = Cl, Figure 1.16), due to the strong binding strength to sulfur
donor atoms in proteins.45 The mechanism of action was proposed to be similar to that
of cisplatin (see Figure 1.2), with the exception that ruthenium(II) complexes stabilise
DNA at pH > 7, which prevents replication.61 However, at pH < 7, RAPTA compounds
caused DNA damage.61 Ruthenium(II) has also been observed to mimic endogenous
iron by binding to proteins.62 Piano-stool complexes (1.29, Figure 1.16) prefer binding
to proteins over DNA, which is an advantage as this reduces the cytotoxicity towards
normal cells.63
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Figure 1.16: General structures of piano-stool complexes of RAPTA (1.28), and
rhodium and iridium (1.29).
Variations based on the RAPTA-C complex have been synthesised to improve the
cytotoxicity and the bio-availability in cells. One such modification is to use biologi-
cally active, naturally occurring compounds and modify these using the RAPTA met-
alloframework. Novel ruthenium complexes bearing curcumin-like structures have been
synthesised and tested for biological activity (1.30, Figure 1.17).64 These complexes
were found to be highly toxic towards both A2780 and A2780cisR cell lines (0.36 µM
< IC50 < 1.18 µM ), as well as having a low affinity toward healthy cells at these con-
centrations. The derivatised curcumin complexes, under high chloride concentration,
reverted to RAPTA-C, as well as an aqua species (Scheme 1.1).64
Figure 1.17: General structure of ruthenium curcumin based complexes investigated
by Dyson and co-workers.64
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Scheme 1.1: Aquation of ruthenium bisdemethoxycurcumin complexes investigated
in 100 mM NaCl(aq)/DMSO at 37 °C for 7 days.64
Another study investigated the impact of enantiomerically pure chiral ligands coordi-
nated to the RAPTA framework.65 Different optical isomers have been found to exhibit
different biological activities; tragically discovered with the administration of thalido-
mide for the treatment of pregnancy pains.66 Dyson and co-workers derivatised the
arene group of the RAPTA framework using R- and S- amido moieties (1.31 and 1.32,
Figure 1.18).65 Upon addition of water, a similar trend in the hydrolysis of RAPTA
compounds was observed (see Scheme 1.1), and the labile chlorido ligands were dis-
placed. In comparison to oxaloRAPTA-C (1.32, Figure 1.18) and the R-configuration,
the S-configuration was found to be highly active against A2780 and A2780cisR cell
lines. However, at the most active concentration, low selectivity between the A2780
cell lines and the HEK (human embryonic kidney) cell line was observed.65
Figure 1.18: Structures of enantiomeric ruthenium complexes investigated by Dyson
and co-workers.65
Dyson’s RAPTA complexes have been the most successful piano-stool ruthenium-based
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drug candidates to date.33 Another study investigated the effects of different metals
with PTA as the ligand based on the RAPTA structure.67 Rhodium (1.33, Figure 1.19)
and Osmium derivatives (1.34, Figure 1.19) of RAPTA were evaluated against the
HT29, A549 and T47D cell lines. Complexes 1.33 showed comparative, and some bet-
ter, antiproliferative activity than the ruthenium analogues in vitro.67 These complexes
were observed to hydrolyse almost completely, making both DNA and proteins possible
targets.67
Figure 1.19: Generic structures of Rhodium (1.33) and Osmium (1.34) derivatives
of RAPTA complexes investigated by Dyson and co-workers.67
1.9 Rationale for the Current Study
Based on the favourable properties of metal-based drugs, there is a need for further
development to enhance the effects observed. Incorporating two or more successful
strategies into a single metal-based drug can potentially enhance or compliment the
effects of the individual strategies.
Two strategies extensively investigated by Smith et al. is the use of functionalised
(N,O)-salicylaldimine complexes and the use of a PTA derivative to increase the water
solubility of these complexes.59,68–73 The first series of these complexes to show com-
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parable activity to cisplatin was prepared by Govender and co-workers70, where the
investigation of propyl-terminated salicylaldimines with ruthenium p-cymene as the
metal component was examined. The use of rhodium and iridium Cp* with various
(N,O)-salicylaldimine ligands were also investigated with largely similar success as the
ruthenium compounds.59,71,72,74 Substitution of the chlorido ligand with a phosphorus
donor ligand, such as PTA, resulted in an increase in biological activity in both A2780
and A2780cis ovarian cancer cell lines.68,71 This shows the importance of the PTA
moiety for biological activity, as observed for Dyson’s original RAPTA complexes.33
Figure 1.20 is a representative structure of the complexes investigated by Govender
and co-workers.59,68,70,71
Figure 1.20: General structure of the complexes investigated by Govender and co-
workers.59,68,70,71
A balance between hydrophilicity and lipophilicity is a key component for the cytotox-
icity of compounds. Water soluble drugs have gathered interest recently since water is
the main component in biological processes.33,35 RAPTA complexes have shown how
effective PTA is to both water solubility and anticancer properties.21,33,35,67 A method
to change the degree of solubility is to quaternise the PTA moiety using organohalides.
Cerrada et al. investigated gold(I) complexes which incorporated various groups at-
tached to PTA.75 Free PTA ligands exhibited no cytoactivity, however the complexes
of these ligands were more active than cisplatin against two Caco-2 colon cancer cell
lines. In addition to the high levels of cytotoxicity against cancerous cells, no activity
was observed against enterocytes when tested at the IC50 concentrations. Burgoyne
et al. investigated the effects of similar quaternary derivatives of PTA using benzyl
halides and platinum group metals.73 These PTA complexes were found to have a de-
gree of water solubility similar to free PTA, which is favourable for the distribution of
21
Chapter 1
drugs in a biological system. The complexes were tested and exhibited activity against
the WHCO1 cell line, but were found to be considerably less effective than cisplatin.
Incorporation of both alkylated PTA and salicylaldimine PGM complexes and their
effect on activity is yet to be investigated. The lipophilicity of the salicylaldimine
complexes and the water solubility of the PTA moiety can potentially enhance the
biological activity of the overall complex. In this study, we aimed to investigate a
series of neutral salicylaldimine PGM complexes and their cationic PTA derivatives
against the MCF-7 breast carcinoma cell line.
1.10 Aims and Specific Objectives
1.10.1 Aims
As discussed in this chapter, it may be interesting to investigate the benefits of both
salicylaldimine PGM complexes68,70,74,76 and an alkylated PTA scaffold as part of the
same complex.73,77 This study therefore is aimed to synthesise a range of PGM sali-
cylaldimine complexes and evaluate their biological activity against the MCF7 breast
adenocarcinoma cell line. These complexes were reacted with an alkylated PTA scaf-
fold77 and the biological significance was evaluated and compared to the non-PTA
analogues.
1.10.2 Specific Objectives
1. To synthesise a series of salicylaldimine ligands (Figure 1.21) containing various
groups on the imine nitrogen.
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Figure 1.21: Salicylaldimine ligands synthesised in this study.
2. To prepare a series of Ru(II), Rh(III) and Ir(III) salicylaldimine complexes (Fig-
ure 1.22). Six of these complexes were previously reported to show activity
against the A2780 human ovarian cell line.68–70,70
Figure 1.22: General structures of (N,O)-salicylaldimine complexes synthesised in
this study.
3. Using the complexes outlined in Figure 1.22, a PTA scaffold to be incorporated
as part of the complexes to afford PTA derivatives (Figure 1.23). PTA complexes
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have shown great in vitro activity,35 as well as favourable biological significant
features such as enhanced water solubility.
Figure 1.23: General structures of (N,O)-salicylaldimine PTA complexes synthesised
in this study.
4. To characterise all of the compounds synthesised using Nuclear Magnetic Reso-
nance spectroscopy (NMR), Fourier Transform - Infrared spectroscopy (FT-IR),
Elemental Analysis (EA) and Electrospray Ionisation (positive mode) or Electron
Impact Mass Spectroscopy (ESI-MS or EI-MS). Single crystal X-ray diffraction
(XRD) analysis was used on single crystals to provide further insight into the
structure of some of the isolated complexes.
5. Lastly, to investigate the in vitro activity of these complexes against the MCF7
breast cancer cell line. To conduct NMR studies to determine a potential biolog-
ical pathway for the most active complex.
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Synthesis and characterisation of
neutral Ru(II), Rh(III) and Ir(III)
salicylaldimine complexes
2.1 Introduction
In light of the high levels of toxicity and unfavourable side effects of cisplatin, a range
of biologically active organometallic complexes have been researched in order to treat
various cancers with minimal side effects.1 Platinum group metals have shown excep-
tional promise, with a few complexes performing well in clinical trials.2,3 Many of these
organometallic compounds have a piano-stool structure, with a η6-para-cymene (pcy)
or η5-pentamethylcyclopentadienyl (Cp*) seat with three legs (Figure 2.1). The dimeric
precursors ([MCl2(pcy or Cp*)]2) of these complexes have been shown to exhibit little
biological activity,4,5 strongly suggesting that the activity of these complexes is deter-
mined by the nature of the ligands attached to the metal. Recently, McGowan and
co-workers4,5 have observed an increase in activity of these organometallic complexes
when the dimer was coordinated to N,N -, N,O- or O,O- bis-chelating ligands, where
the N,O complexes were found to exhibit the greatest activity amongst the three types.
This result suggests that N,O- bis-chelating ligands coordinated to these metals can
produce highly cytotoxic complexes, making them favourable for anticancer research.
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Figure 2.1: Structure of piano stool complexes, with a piano-stool in the centre for
comparison.
Salicylaldimines are versatile and easily functionalised building blocks for larger macro-
molecules and can be used in a wide range of biological applications.6–12 Many salicyl-
aldimines enhance the distribution of the metal into organelles and interrupt DNA pro-
cesses, increasing the activity of the complex.13 In addition to this, the N,O-chelating
ligand can be attached to a pharmacophore to infiltrate biological targets.9,14,15 Various
salicylaldimine PGM complexes exhibit moderate or low activity against the human
ovarian cancer cell lines, A2780 and A2780cis (I, Figure 2.2),9,16. However, in other
cell lines, namely MCF7 (human breast carcinoma) and A549 (lung cancer), similar
complexes showed comparable activity to cisplatin (II, Figure 2.2).17,18
Three biologically active groups of interest for this project are the ferrocenyl, trifluo-
romethyl and trimethylsilane groups, which have shown biological activity in previous
studies.19–21 Ferrocene is chemically robust and highly versatile. The most promis-
ing feature of ferrocene for biological applications is its ability to promote single
electron redox transfers.22 Ferrocenyl analogues of biologically active tamoxifen and
raloxifene (ferrocifens and ferrocenyl raloxifenes) have been shown to have high cy-
totoxicity in various invasive cancer cell lines in vitro, as well as following the same
selective estrogen receptor modulator (SERM) mechanism of action.23 Fluorine groups
have shown promise in the inhibition of various important biological processes for tu-
mour growth.19,24 The small size of the fluorine group, its high electronegativity and
resistance to chemical degradation, makes fluorine-containing compounds favourable
for enzyme inhibition.24 Various fluorine-containing compounds have shown potent
anticancer properties, for example TAS-102. TAS-102 is a potent combination anti-
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Figure 2.2: Selected salicylaldimine complexes investigated by Smith et al.9,16 (I) and
Zhang et al.10,11,17,18 (II).
cancer treatment for third- and fourth- line colorectal cancers. The treatment combines
both antiangiogenic and thymidylate synthase inhibition properties, with Trifluricine,
a (trifluoromethyl)pyrimidine-2,4-dione deoxyribose compound, responsible for the in-
hibition of tumour growth.25 Very few silane-based compounds are reported in the
literature as potential anticancer agents. A few reports have shown these groups to
be more active than analogous carbon derivatives.20,21 Silanes are highly lipophilic in
nature, which can be advantageous for cross-membrane transfer between lipo- and hy-
drophilic boundaries.
Since very little research has been done to investigate the biological activity of tri-
fluoromethane and organosilane salicylaldimine complexes, this study investigates the
synthesis and characterisation of trifluoromethane- and organosilane- derivatised sali-
cylaldimine complexes, as well as ferrocenyl- and propylsalicylaldimine complexes pre-
viously reported by Smith and co-workers.9,15,16,26
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2.2 Synthesis of (N,O)-salicylaldimine ligands
2.2.1 Synthesis
Four salicylaldimine ligands were synthesised using modified literature methods.16,27
Salicylaldehyde was reacted with either n-propylamine, 4-trifluoroaniline or 3-amino-
propyl trimethylsilane via a Schiff-base condensation reaction to afford ligands 2.1-
2.3 (Scheme 2.1).16,27 The electrophilic formyl carbon of salicylaldehyde undergoes
nucleophilic attack from the electron-rich nitrogen of the amine (Scheme 2.2). The
oxygen atom accepts the electrons from the carbonyl bond and by means of a proton
transfer reduces to a hydroxyl group. A sequence of bond forming (C-N to C=N) and
bond breaking (C–OH) due to rearrangement results in the formation of the imine
product and water. The Schiff-base products were isolated as either viscous yellow
oils (compounds 2.1 and 2.3) or an amorphous yellow powder (2.2) in high yields
(91-93%).
Scheme 2.1: Synthesis of (N,O)-chelating Ligands, 2.1-2.3. Reagents and conditions:
(a) n-propylamine / Et2O / 18 h / r.t.; (b) 4-trifluoromethylaniline / Et2O / 16 h /
r.t.; (c) 3-aminopropyltrimethylsilane / Et2O /16 h / r.t.
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Scheme 2.2: Reaction mechanism of the Schiff-base condensation reaction to afford
2.1-2.3.
Compound 2.4 was synthesised in a two-step process from salicylaldehyde hydrazone,
L1, which was prepared by reacting salicylaldehyde and hydrazine hydrate (Scheme 2.3),
using a modified literature method,15 and was isolated as a beige crystalline solid in
low yield (34%). Compound 2.4 was synthesised via the same mechanism as outlined
before (Scheme 2.2) using L1 and ferrocenecarboxaldehyde (Scheme 2.4). Compound
2.4 was isolated as a deep red amorphous solid in high yield (75%).
Scheme 2.3: Synthesis of L1.
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Scheme 2.4: Synthesis of 2.4.
2.2.2 Characterisation
Ligands 2.1-2.4 and L1 were characterised by various spectroscopic and analytical
techniques, namely 1H, 13C{1H}, 19F{1H} (compound 2.2), 1H-1H correlation spec-
troscopy (COSY) and heteronuclear single quantum coherence (HSQC) nuclear mag-
netic resonance (NMR) spectroscopy, infrared (IR) spectroscopy, and electron impact
(EI-MS).
NMR Spectroscopy
Analysis of the 1H NMR spectra of compounds 2.1-2.4 and L1 confirmed that the pro-
posed compounds were obtained. All spectra were recorded in CDCl3 and the absence
of the CHO resonance at δH 9.87 ppm, observed in the spectrum of the aldehyde, con-
firmed successful Schiff-base condensation. The presence of a singlet in the 1H NMR
spectra of 2.1-2.4, in the region of δH 8.3-8.7 ppm, confirmed the presence of the imine
group (Table 2.1). Phenyl proton resonances for the salicylaldimine spin system were
observed in the region of δH 6.7-7.6 ppm, integrating for four protons. The hydroxyl
proton is deshielded because of the attached phenyl group and was found to be in
the region above δH 11 ppm in spectra of 2.1-2.4 (Table 2.1). The integration of the
proton resonances were consistent with the proposed structures.
The spectrum of 2.1 displayed signals pertaining to the propyl chain which was ob-
served at δH 1.00 (t), 1.74 (m) and 3.56 (td) ppm for the CH2CH3, CH2CH3 and
NCH2CH2 protons, respectively. Due to the effect of the trimethylsilane group in 2.3,
the signals of the propyl chain differ to those of 2.1. In comparison to the spectrum of
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2.1, the CH2Si(CH3)3 proton resonance was observed at δH 0.58 ppm. Signals for the
CH2CH2Si and NCH2CH2 protons were observed at δH 1.72 (m) and 3.60 (t) ppm,
which are comparable to resonances observed for the same protons in 2.1. In the 1H
NMR spectrum of 2.2, additional aromatic signals were observed at δH 7.36 (2H) and
7.77 (2H) ppm as doublets due to the 1,4-substituted ring.
The synthesis of L1 was supported by the appearance of a singlet at δH 7.87 ppm
(CHN), integrating for 1H. Confirmation of the monofunctionalised product was the
appearance of a broad singlet at δH 5.43 ppm, integrating for 2H, which was assigned
to the NH2 of the hydrazone. The OH resonance was observed at δH 11.05 ppm, and
integrated for a single proton. In the 1H NMR spectrum of 2.4 a shift of the imine
resonance in L1 from δH 7.87 ppm to 8.56 ppm suggests a change in the environment of
the CHN moiety. An additional imine proton resonance was observed at δH 8.67 ppm
for the imine group adjacent to the ferrocenyl moiety. In the COSY spectrum of 2.4
the imine signal at δH 8.70 ppm was observed to be correlated with one of the aromatic
signals of the salicylaldimine (Figure 2.3), confirming the correct assignment. Signals
for both the substituted (δH 4.51 (2H) and 4.74 (2H) ppm) and unsubstituted (δH 4.25
(5H) ppm) cyclopentadienyl groups are observed, confirming successful synthesis.
Table 2.1: Selected resonances observed in the 1H NMR spectra of ligands 2.1-2.4,
recorded in CDCl3
Compound CHN (δH , ppm) RC6H4OH (δH , ppm)
2.1 8.33 13.66
2.2 8.68 12.80
2.3 8.35 13.71
2.4 8.70 11.84
13C{1H} NMR spectroscopy was used to further characterise compounds 2.1-2.4. Sig-
nals pertaining to the imine carbon atoms (C=N) were assigned at approximately δC
164 ppm for compounds 2.1-2.4. Signals for the COH carbon were observed at δC 161
ppm. In the spectrum of 2.2, C-F coupling was observed for the carbons closest to the
fluorine atoms. Coupling constants for 1JC−F , 2JC−F and 3JC−F were observed and
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Figure 2.3: COSY spectrum of 2.4, in CDCl3, with a box enclosing the cross-peak
of protons 6 and 8.
found to be 272.0 Hz, 32.5 Hz and 3.7 Hz, respectively, and the signals were observed
as quartets (Figure 2.4). This phenomenon is consistent with the reported literature
of similar compounds.28 In the spectrum of 2.3, the signal associated with Si(CH3)3
was observed at δC -1.79 ppm due to the high shielding nature of the silicon atom.
Compound 2.2 was analysed using 19F{1H} NMR spectroscopy. A single resonance
was observed at δF -62 ppm, evidence of a single fluorine species.
Infrared Spectroscopy and EI Mass Spectrometry
Infrared (IR) spectroscopy is a technique used to identify various functional groups
within a given molecule. The IR spectra of 2.1-2.4 were recorded in the solid state
using the attenuated total reflection (ATR) sampling technique. The spectra of com-
pounds 2.1-2.4 displayed absorption bands for the imine C=N between 1585 and 1618
cm−1.
EI-MS analysis further confirmed the proposed structures. Molecular ion peaks were
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Figure 2.4: 13C{1H} NMR spectrum of 2.2 in CDCl3, highlighting key carbon regions
and assignments.
observed at m/z 163.00, 265.01, 235.13 and 332.05 in the spectra of 2.1, 2.2, 2.3 and
2.4, respectively, further supporting the proposed structure.
Based on the characterisation data obtained, it was concluded that a series of (N,O)-
salicylaldimine ligands were successfully synthesised. All spectroscopic and analytical
evidence confirmed the integrity of the compounds synthesised.
2.3 Synthesis of (N,O)-salicylaldimine Ru(II), Rh(III)
and Ir(III) complexes
2.3.1 Synthesis
A series of (N,O)-salicylaldimine Ru(II), Rh(III) and Ir(III) complexes, 2.5-2.16, was
synthesised using the afore-mentioned synthesised ligands via a bridge splitting reaction
of [RuCl(µ-Cl)(p-cymene)]2, [RhCl(µ-Cl)(Cp*)]2 or [IrCl(µ-Cl)(Cp*)]2 (Scheme 2.5).
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Complexes 2.5-2.7, 2.8-2.10, 2.11-2.13 and 2.14-2.16 were synthesised by reacting
2.1, 2.2, 2.3 and 2.4, respectively, in the presence of triethylamine to deprotonate the
hydroxyl group, with the corresponding metal dimer to form the (N,O)-complexes.
Complexes 2.5-2.10 were synthesised in dichloromethane, whereas 2.11-2.13 and
2.14-2.16 were synthesised in diethyl ether and ethanol, respectively.
Scheme 2.5: Synthesis of (N,O)-complexes, 2.5-2.16. Reagents and conditions: (a)
Et3N, [RuCl(µ-Cl)(p-cymene)]2 / r.t.; (b) Et3N, [RhCl(µ-Cl)(Cp*)]2/ r.t.; (c) Et3N,
[IrCl(µ-Cl)(Cp*)]2/ r.t.
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2.3.2 Characterisation
NMR Spectroscopy
The 1H and 13C{1H} NMR spectra of 2.5-2.16 were recorded in CDCl3 and are con-
sisted with the proposed structures.
Coordination was confirmed by an upfield shift in the imine proton (CHN) resonance.
A shift from δH 8.33 ppm in 2.1 to δH 7.67-7.80 ppm in the complexes confirmed
coordination to the imine nitrogen. The absence of the phenolic proton signal of the
salicylaldimine moiety further supports the proposed bidentate chelation of the ligand
to the metal centre. A consequence of this is metal chirality, as the metal becomes a
stereogenic centre. Since there are no factors influencing the coordination site of the
imine, two enantiomers are formed in equal probability (racemic mixture). Evidence
of this is the diastereotopic behaviour of signals 2 and 3 (Figure 2.5), where the CH2
protons are seen as non-equivalent in complex 2.5, but are equivalent in the spectrum
of ligand 2.1. The same diastereotopic behaviour is observed in 2.6 and 2.7. In the
13C{1H} NMR spectra of 2.5-2.7, an upfield shift of the imine carbon resonance from
the free ligand (δC 164.5 ppm) to the complex (δC 159-163 ppm) is also observed,
thus confirming coordination to the imine nitrogen. A downfield shift of the carbon
resonance adjacent to the oxygen atom (δC 161 ppm to 165-166 ppm) strongly suggests
a metal-oxygen bond thus supporting the notion of the ligand behaving as an (N,O)-
chelating ligand.
In the 1H NMR spectra of 2.8-2.10, an upfield shift in the imine proton signal was ob-
served (δH 7.7-8.0 ppm) when compared to the free ligand (δH 8.68 ppm). Minute shifts
in the (trifluoromethyl)phenyl group suggest little to no interaction with the p-cymene
or Cp* ligands on the metal. A small shift in the carbon resonance for the imine group
was observed. In the 13C{1H} NMR spectra of 2.8-2.10, a distinct downfield shift
of the carbon adjacent to the nitrogen from δC 151 ppm to 160-161 ppm (Figure 2.6)
confirmed bonding of the nitrogen atom to the metal centre. The imine carbon res-
onance exhibited minor shifts from δC 164 ppm to 161-164 ppm. Coupling constants
and carbon resonances for the trifluoromethylaniline group observed in the 13C{1H}
NMR spectrum of 2.2 are unaffected in the complexes 2.8-2.10, further suggesting
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Figure 2.5: 1H NMR spectra comparison of 2.1 and 2.5 in CDCl3.
that there is no interaction of the p-cymene or Cp* ligands with the trifluormethane
group. This was further confirmed using 19F{1H} NMR spectroscopy. As observed in
2.2, a single resonance was observed at δF -62 ppm for 2.8-2.10 which supports the
notion of a single fluorine species.
Figure 2.6: 13C{1H} NMR spectra comparison in the region between δC 150 and 170
ppm of 2.2 and 2.8 in CDCl3.
The 1H NMR spectra of complexes 2.11-2.13 display similar phenomena to those ob-
served in complexes 2.5-2.7. Evidence of chirality is observed in the signals associated
with the propyl chain. Each CH2 proton of the propyl chain was observed at its own
chemical shift and integrates for a solitary proton. An upfield shift of the imine signal
from δH 8.35 ppm to 7.6-7.6 ppm (Figure 2.7) is indicative of a change in the chemical
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environment of the imine substructure. No hydroxyl signal (Figure 2.7) was observed
in the 1H NMR spectra, strongly suggesting that the ligand was deprotonated in the
synthesis process. As found for complexes 2.5-2.7, resonances for the imine and CO-
M carbon atoms in the 13C{1H} NMR spectra were observed to have an upfield or
downfield shift, respectively.
Figure 2.7: 1H NMR spectra comparison in the region between δH 6.0 and 8.5 ppm
of 2.3 and 2.12 in CDCl3.
A shift of the imine proton signal in the 1H NMR was observed upon complexation
from 2.4 (δH 8.70 ppm) to 2.14-2.16 (δH 7.80-8.31 ppm). A minor shift in the imine
proton resonance adjacent to the ferrocenyl group, confirms that the nitrogen adjacent
to the salicylaldimine moiety coordinates to the metal centre. The protons for the
substituted Cp ring are observed in the region of δH 4.2-4.9 ppm and are inequivalent.
Infrared Spectroscopy and Mass (EI and ESI) Spectrometry
For complexes 2.5-2.16, a shift to lower wavenumbers of the C=N stretching vibra-
tion from the free ligands (≈ 1630 cm−1) to the complexes (≈ 1615 cm−1) supports
complexation (Figure 2.8). The lower wavenumber suggests a weakening of the C=N
bond. The metal-nitrogen bond is strengthened by back-bonding of the metal into
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the nitrogen pi∗ orbital, which in turn reduces the bond order between the carbon and
nitrogen. This synergistic effect is commonly observed in metal-imine systems.16,29
Figure 2.8: Representative IR spectra comparison between the ligand (2.1) and
complex (2.5) highlighting the region of the imine absorbance.
The EI-MS spectra of complexes 2.5-2.7 and 2.14-2.16 and ESI-MS spectra of com-
plexes 2.8-2.13 supports the synthesis of the proposed structures. Complexes were
either ionised as M+ or [M+H]+ and corresponded well to the calculated values, with
the exception of 2.13. Compound 2.13 was observed to lose both the Cl and three
methyl groups of the silane ([M-Cl-(CH3)3]
2+), with an overall charge of 2+.
Single Crystal X-Ray Diffraction (XRD)
Single crystal XRD is a useful technique to confirm the molecular structures of proposed
compounds. Single crystals of 2.8-2.10 were obtained by slow diffusion of diethyl
ether into methanol and the structures of these complexes elucidated (Figure 2.9).
These complexes crystallised in the P21/c space group with 4 molecules present in
a given unit cell. The geometry about the metal is consistent with the proposed
piano-stool geometry, with the angles between the N,O and Cl donor atoms ranging
between 85 and 89°, indicative of a pseudo-tetrahedral arrangement (Table 2.2). This
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is consistent with the data obtained by Smith et al. for complex 2.5.16 The two phenyl
groups are observed to be ∼ 90° in relation to each other. A six-membered ring is
formed between the (N,O)-chelating ligand and the metal centre, further supporting
the proposed bidentate structure. Bond distances between the metal and chlorido
ligand are 20% larger in comparison to the N,O-chelate and the arene/Cp* group (2.0
A˚ for N,O compared to 2.4 A˚ for chlorido, see Table 2.2). Torsion angles about the
imine bond are observed to be 179°, confirming a trans-configuration of the imine. The
crystal data are provided in Table 2.3.
Figure 2.9: Ball and stick representation of the molecular structures of 2.8-2.10
determined by single crystal XRD. Hydrogen atoms are omitted for clarity.
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Table 2.2: Selected bond distances and angles of complexes 2.8-2.10
Bond distance (A˚) / angle (°)
Entity 2.8 2.9 2.10
M-N 2.088(2) 2.109(2) 2.095(3)
M-Cl 2.4288(8) 2.4258(9) 2.4210(9)
M-O 2.0594(18) 2.068(2) 2.084(2)
N-M-O 88.01(7) 88.42(8) 88.02(10)
N-M-Cl 89.89(9) 85.18(7) 85.59(7)
O-M-Cl 85.38(6) 88.89(7) 85.58(7)
C=N-C-C 179.9(3) 179.9(3) 178.7(3)
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Table 2.3: Crystal data and structure refinement for complexes 2.8-2.10
2.8 2.9 2.10
Empirical Formula C24H23ClF3NORu C24H24ClF3NORh C24H24ClF3IrNO
Formula Weight (g.mol−1) 534.95 537.80 627.11
Temperature (K) 110 173 173
Radiation (A˚) 0.71073 0.71073 0.71073
Crystal System Monoclinic Monoclinic Monoclinic
Space Group P21/c P21/c P21/c
Unit Cell dimensions
a (A˚) 9.6891(5) 11.8815(14) 7.7409(6)
b (A˚) 13.8341(7) 24.057(3) 22.0339(15)
c (A˚) 16.7075(7) 7.8436(10) 12.9297(9)
α (°) 90 90 90
β (°) 96.279(1) 103.124(3) 95.103(2)
γ (°) 90 90 90
V (A˚3) 2226.04(19) 2183.4(5) 2196.6(3)
Z 4 4 4
Density (calc.) (g·cm−1) 1.596 1.636 1.896
F (000) 1080 1088 1216
Crystal size (mm) 0.07 x 0.08 x 0.08 0.13 x 0.14 x 0.15 0.09 x 0.13 x 0.16
θmin,max (°) 1.9, 27.9 1.7, 28.0 1.8, 28.0
Data set -12 : 12 ; -18 : 18;
-21 : 21
-15 : 15 ; -31 : 31;
-10 : 9
-10 : 10 ; -29 : 29;
-17 : 17
Total reflections 43241 26557 44304
Unique reflections 5332 5269 5291
R indices (R1, wR2) 0.0320, 0.0666 0.0359, 0.0837 0.0224, 0.0516
Res. Dens. (e A˚−3)min,max -0.52, 0.46 -0.55, 0.60 -0.59, 0.96
Based on the correlation between the proposed structures and the spectroscopic data,
it can be concluded that the desired metal complexes were synthesised.
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2.4 Summary
A series of salicylaldimine complexes was prepared, characterised and the data obtained
from compounds 2.5-2.8 and 2.14-2.16 corresponded well to the literature.9,15,16,26
Two new series of trifluoromethane (2.8-2.10) or organosilane (2.11-2.13) complexes
bearing Ru(II), Rh(III) or Ir(III) metal centres, derived from two salicylaldimine lig-
ands (2.227 and 2.3) were synthesised and characterised. Single crystals of 2.8-2.10
were analysed by X-ray diffraction and further confirmed the molecular structure of
the complexes in the solid state. All of the compounds were characterised using NMR
(1H, 13C{1H}, HSQC, COSY) and IR spectroscopies, elemental analysis, and EI (2.5-
2.7 and 2.14-2.16) or ESI (2.8-2.13) mass spectrometry and correlate well with the
proposed structures.
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Synthesis and characterisation of
cationic Ru(II), Rh(III) and Ir(III)
alkylated PTA complexes
3.1 Introduction
Despite extensive investigation of the potential anticancer activity of various metal-
based compounds, only a few have entered clinical trials.1,2 Three platinum-containing
complexes are currently used clinically.3 Issues such as in vivo toxicity, drug resistance
and low aqueous solubility all contribute to the low success rate of metal complexes
as anticancer agents.4 The severe side-effects of widely-used cisplatin and problems
such as tumour resistance, have led to the investigation of more effective and less toxic
alternatives.
Ruthenium complexes such as NAMI-A and KP1019 have shown promise and have been
evaluated in clinical trials.5–9 Recently, ruthenium(II) arene complexes have become
a popular alternative to these ruthenium(III) coordination complexes. Specifically,
compounds of the RAPTA variety ([Ru(η6-arene)(PTA)L2], 1a, Figure 3.1) have shown
great promise and could be used as anticancer agents in the future.10,11 Generally,
RAPTA complexes contain a ruthenium core, an arene group and the PTA (1,3,5-
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triaza-7-phosphaadamantane) ligand, which promotes aqueous solubility, as well as two
labile chlorido ligands. These complexes have shown potent antitumour activity against
both primary and metastatic tumours in vivo.12–15 Increasing the cellular uptake and
changing the metal can increase the bio-activity of these complexes. Dyson and co-
workers16 investigated the effect of lipophilicity by changing the arene, changing a Cl
ligand to PPh3, and altering the counter ion to increase cellular uptake. A 10-fold
increase in cytotoxicity was observed by changing the counterion to a BF4 species (1a,
2a to 1b, 2b, respectively, Figure 3.1), whilst the p-cymene arene complex showed the
greatest activity. A slight increase in the uptake of 1b in comparison to 1a (Figure 3.1)
in cells (0.13 vs 0.12 µg per 106 cells) suggests that a small change in the uptake can
assist with the activity of the complex in question.
Figure 3.1: PTA complexes investigated by Dyson and co-workers.16
Another way to tailor RAPTA complexes to biological assays is to increase the solubility
of the complexes in the medium. To increase the water solubility, Burgoyne and co-
workers17 used benzyl chloride and 1,3,5-tris(chloromethyl)benzene to create a charge
on the PTA ligand using an alkylation reaction. These complexes, shown in Figure 3.2,
exhibit significant water solubility, as well as biological activity. These complexes were
evaluated against an oesophageal cancer cell line (WHCO1), and was observed to have
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a biological profile 5-33 times less effective than cisplatin against the WHCO1 cell line.
The other way to tailor these complexes is to replace the chlorido ligands with more
biologically significant entities. Changing the ligands can significantly change the inter-
action with biomolecules and may display more effective modes of action.18 Pettinari
et. al.12 displaced these chlorido ligands with (O,O)-curcumin derivatives, which have
shown promise in a previous study.19 In comparison to cisplatin, these complexes were
more active against the ovarian carcinoma sensitive and resistant A2780 and A2780cis
cancer cell lines, and display comparable activity against the non-tumorous human
embryonic kidney cells (HEK293), with the most active complex being 71% less toxic
to HEK293. These complexes also exhibited no preference between the resistant and
sensitive cancer cell lines (Resistance Index (RI) ' 1, A2780cis/A2780 (cisplatin, RI
= 17)), as well as high selectivity for A2780 over HEK293, with the selectivity indices
(SI) of these complexes ranging between 12 and 65 in comparison to cisplatin (SI =
5).19
Figure 3.2: Alkylated PTA complexes investigated by Burgoyne and co-workers.17
These changes to the RAPTA series have yielded significant improvements in the up-
take, solubility and selectivity of these compounds.12,16,17,19 In this chapter, a series of
alkylated PTA Ru(II), Rh(III) and Ir(III) complexes, an extension of the work con-
ducted by Burgoyne and co-workers17 were prepared in order to investigate the effect
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of incorporating an alkylated PTA scaffold and its influence on biological activity in
comparison to the complexes discussed in Chapter 2. The biological activity of PTA
complexes containing metals other than ruthenium has been infrequently explored.20
The synthesis and characterisation of the complexes are reported herein.
3.2 Synthesis of the alkylated PTA scaffold and
monocationic complexes (3.1-3.4)
3.2.1 Synthesis
A benzyl alkylated PTA scaffold (3.1) was synthesised by reacting one molar equivalent
each of benzyl chloride and 1,3,5-triaza-7-phosphaadamantane via a quaternisation
reaction to afford the benzyl PTA scaffold (3.1, Scheme 3.1). The reaction proceeds
via a nucleophilic substitution reaction of the chloride with a tertiary PTA amine
(Scheme 3.1). No bis-functionalised product was obtained, even when reacting 2.5
molar equivalents of benzyl chloride, likely due to the close proximity of the positive
charges. The atom economic product was isolated as a white solid, in high yield (99
%) and was found to be soluble in water, dimethyl sulfoxide, alcohols and sparingly
soluble in chloroform.
Scheme 3.1: Synthesis of the benzyl PTA scaffold, 3.1, with the reaction mechanism.
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RAPTA-type complexes were synthesised by reacting [RuCl(µ-Cl)(p-cymene)]2, [RhCl(µ-
Cl)(Cp*)]2 or [IrCl(µ-Cl)(Cp*)]2 with the benzyl PTA scaffold (3.1) via a bridge-
splitting reaction (3.2-3.4, Scheme 3.2). The complexes were isolated as red crystalline
(3.2 and 3.3) or orange amorphous (3.4) powders in moderate yields (50-70 %), and
were found to be highly water-soluble, in contrast to the metal dimers.
Scheme 3.2: Synthesis of the metal PTA complexes 3.2-3.4.
3.2.2 Characterisation
NMR Spectroscopy
Analysis of the 1H NMR spectrum of 3.1 shows that the mono-quaternised PTA scaf-
fold was obtained. Two AB-spin quartets, integrating for 4H and 2H, were observed in
the spectrum, supporting a loss of the C3v symmetry. These signals were assigned to
the lower cage protons of the PTA moiety (signals 6 and 7, Figure 3.3). The protons of
the upper cage (carbon atoms adjacent to the phosphorus atom) were also observed as
two sets of signals, with an undefined splitting pattern, further supporting the loss of
symmetry of the free PTA precursor and coupling to the NMR active 31P nucleus. A
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singlet for the benzyl CH2 protons was observed at δH 4.2 ppm and integrated for 2H.
A broad multiplet was observed at δH 7.5-7.6 ppm assigned to the aromatic protons,
integrating for 5H. Upon complexation with the metal dimers, the AB-spin system was
not observed, supporting a change in the PTA environment. Upon complexation of
3.1, proton resonances for the aromatic signals (signals 1-3, Figure 3.3) appear more
distinct.
Figure 3.3: 1H NMR spectrum of 3.1 in CD3OD-d4.
Two signals for the methyl carbon atoms of the Cp* moiety of 3.3 in the 13C{1H}
NMR spectrum are observed in CD3OD-d4 (Figure 3.4). This phenomenon was not
observed in CDCl3 (Figure 3.4), for complexes 3.2 and 3.4 and the dimeric precursor.
Further investigations are required to understand this phenomenon. The 31P{1H} NMR
spectra of compounds 3.1-3.4 provided further support that the proposed compounds
were synthesised. A singlet at δP -81 ppm (3.1, Figure 3.5) for the phosphorus atom of
the PTA ligand 3.1 was observed (a significant shift from the free PTA precursor, which
was observed at δP -98 ppm). Upon complexation, a downfield shift of the phosphorus
resonance from δP -81 ppm to ∼ -21 ppm for 3.2 and 3.3 and δP -55 ppm for 3.4
(Figure 3.5) confirms a change in the environment of the phosphorus atom, evidence
of the formation of a metal-phosphorus bond. Coupling of the rhodium centre and the
phosphorus atom is evident in the 31P{1H} NMR spectrum of 3.3, with the phosphorus
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signal observed as a doublet with a coupling constant of JRh−P = 150 Hz.
Figure 3.4: 13C{1H} NMR spectra of 3.3 in CD3OD-d4 and CDCl3, showing the Cp*
methyl carbon signals.
Figure 3.5: 31P{1H} NMR spectra comparison of 3.1-3.4, in CD3OD-d4 (3.1) and
CDCl3 (3.2-3.4).
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ESI Mass Spectrometry
The ESI mass spectra, recorded in the positive-ion mode, of 3.1-3.4 confirmed the
successful synthesis of the proposed compounds. The spectra of compounds 3.1-3.3
display a base peak of [M-Cl]+ (248.1318, 554.0833, 556.0906 respectively), while a
peak for [M-2Cl]2+ (305.5901) is observed for 3.4. These results are consistent with
the proposed structures.
3.3 Synthesis of dicationic (N,O)-salicylaldimine PTA
complexes (3.5-3.15)
3.3.1 Synthesis
Complexes 2.5-2.11 and 2.13-2.16 (discussed in Chapter 2) were reacted with 3.1 to
afford complexes 3.5-3.15 (Scheme 3.3). Complexes 2.5-2.7, 2.11, 2.13 and 2.14 were
reacted under an inert atmosphere with 3.1 in dry ethanol for 16 hours to afford com-
plexes 3.5-3.7 and 3.11-3.13 as highly water-soluble powders. Complexes 3.8-3.10,
3.14 and 3.15 (unstable as chloride salts) were prepared by abstracting the chlorido
ligand of 2.8-2.10 and 2.15-2.16 using silver hexafluorophosphate in acetone, under
argon, and subsequently reacted with 3.1 to afford the desired complexes as sparingly
water-soluble powders. Complex 2.12 was reacted with 3.1; however the product
formed was not stable as chloride or hexafluorophosphate salts and therefore could not
be isolated for analysis. Ruthenium complexes (3.5, 3.10 and 3.13), though hygro-
scopic, formed insoluble products in water which could be solubilised using DMSO.
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Scheme 3.3: Synthesis of the dicationic PTA complexes 3.5-3.15.
3.3.2 Characterisation
NMR Spectroscopy
Analysis of the 1H NMR spectra of complexes 3.5-3.15 provides strong evidence for
the synthesis of the proposed complexes.
For complexes 3.5-3.7, the most shielded methylene protons of the propyl chain were
observed as a multiplet (δH 1.7-2.2 ppm, Figure 3.6), as opposed to the two multiplets
observed in 2.5-2.7. A similar phenomenon was observed in the spectra of 3.11 and
3.13. Overlap of the upper cage PTA proton resonances and the methylene protons
adjacent to the imine group was observed. A loss of the AB-spin system was observed
for the lower cage proton resonances (signals 6 and 7, Figure 3.3), suggesting coordina-
tion of the PTA moiety to the metal (A, Figure 3.7). The aromatic signals of the PTA
scaffold (3.1) split into an array of signals in the complexes (B, Figure 3.7), further
supporting the proposed structures. In the 13C{1H} NMR spectra, a downfield shift
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of the imine proton resonance was observed from ≈ δC 165 ppm to ≈ 169 ppm. In
contrast to 3.1, three carbon resonances were observed in the spectra of complexes 3.5-
3.7, 3.11 and 3.13 for the upper cage of the PTA moiety as opposed to two observed
in 3.1. Signals for the aromatic carbons of 3.1 are observed, with minor changes upon
complexation.
Figure 3.6: 1H NMR spectra of 2.5 and 3.5 emphasising change in the splitting
patterns from 2.5 (CDCl3) to 3.5 (CD3OD-d4)
Figure 3.7: 1H NMR spectra comparison of 3.1 (circled in green) and ruthenium
propyl PTA complex (3.5) in CD3OD-d4.
Analysis of the 1H NMR spectra of 3.8-3.10 and 3.13-3.15 confirmed that the pro-
posed structures were afforded. An upfield shift of the imine resonance was observed
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for 3.8-3.10 and 3.13-3.15. The Cp* proton resonance of complexes 3.9, 3.10, 3.14
and 3.15 was observed to be a multiplet, likely due to coupling to the phosphorus,
which is observed in literature.21 Significant overlap of the PTA and ferrocenyl protons
are observed in the region of 4.2-4.9 ppm for complexes 3.13-3.15, and signals were
assigned with the aid of 2D NMR techniques. The aromatic protons were observed as
5 multiplets, integrating for 13 protons, which is consistent with the proposed struc-
ture. Due to the low solubility of 3.8-3.10 and 3.14-3.15 in common NMR solvents,
13C{1H} spectra were not obtained for these compounds.
As observed for compounds 3.2-3.4, upon reacting with the complexes obtained in
Chapter 2 (2.5-2.11 and 2.13-2.16), an upfield shift of the phosphorus NMR reso-
nance was observed. Signals for the phosphorus atoms of the ruthenium and iridium
complexes were observed as singlets in the region of δP -20 to -24 ppm (Figure 3.8)
and δP -40 to -55 ppm, respectively. The same signals for the rhodium complexes
are observed as doublets, as the rhodium centre is spin-active, giving rise to a large
coupling constant of 150 Hz. This strongly suggests coordination of the phosphorus
atom to the metal centre. A septet integrating for 2P, resonating at δP -144 ppm with
1JP−F = 708.8 Hz, is observed in the spectra of 3.8 (Figure 3.8), 3.9, 3.10, 3.14 and
3.15 and was assigned to the two PF6 counterions.
Figure 3.8: 31P{1H} NMR spectra comparison of complexes with Cl (3.13), PF6
(3.8) counterions and 3.1 in CD3OD-d4.
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IR Spectroscopy and ESI Mass Spectrometry
Infrared spectroscopy was used to determine the effect of the PTA scaffold on the
imine bond character. A shift of ν(C=N) to lower wavenumbers strongly suggests a
strengthening of the metal-nitrogen bond, lowering the bond order of the C=N bond.
A general trend in a shift towards lower wavenumbers of the imine bands (Figure 3.9)
was observed upon substitution of the chlorido ligand with 3.1 (Table 3.1). Charged
complexes such as 3.5-3.15 have less electron density on the metal, decreasing the pi*-
donor capacity of the metal. This increases the δ-donation of the N→M interaction,
decreasing the bond order of the C=N bond, thus weakening the bond and resulting
in a lower absorption frequency.
Figure 3.9: IR spectrum comparison of 2.5 and 3.5, indicating the imine ν(C=N)
absorption bands.
The ESI-MS spectra further confirmed that the desired complexes were afforded. Com-
plexes 3.5, 3.6 and 3.7 were ionised to [M-Cl]+, with peaks corresponding at m/z
681.2059, 683.2157 and 773.2709, respectively. In the spectrum of 3.11, a peak of
75% relative intensity at m/z 735.2667 was observed. This corresponds to the loss of
both chlorido counterions from the proposed structure, but with addition of a hydroxyl
counterion ([M-2Cl+OH]+). The chloride salt complexes (3.5-3.7 and 3.11-3.13) are
hygroscopic and this fragment is likely a product that forms upon contact with at-
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Table 3.1: Comparison of ν(C=N) absorption bands for complexes 2.5-2.11, 2.13-
2.16 and 3.5-3.15.
M-Cl ν/cm−1 M-PTA ν/cm−1
2.5 1624 3.5 1598
2.6 1627 3.6 1619
2.7 1625 3.7 1625
2.8 1615 3.8 1600
2.9 1603 3.9 1599
2.10 1615 3.10 1602
2.11 1618 3.11 1601
2.13 1619 3.12 1607
2.14 1600 3.13 1599
2.15 1611 3.14 1600
2.16 1618 3.15 1601
mospheric moisture. No dihydroxy species were observed in the high resolution mass
spectra of these complexes. The ferrocenyl complexes, 3.13-3.15, display peaks corre-
sponding to the loss of both counterions. In the negative mode for complexes 3.8, 3.9,
3.10, 3.14 and 3.15, a peak at m/z 144.9647 was observed and assigned to the PF6
counterion. For these complexes, no peak in the region of m/z 35 (Cl−) was observed,
evidence of the successful counterion exchange.
Single crystal X-ray Diffraction
Single crystals of 3.8 were obtained in deuterated methanol in an NMR tube, and the
molecular structure of this complex determined (Figure 3.10). Complex 3.8, like the
precursor 2.8, crystallised in the P21/c space group with four molecules observed in
each unit cell. A disordered arrangement, with a site occupancy factor less than 1.0,
about the p-cymene moiety was observed. The geometry around the metal is pseudo-
tetrahedral, similarly observed in 2.8. Minor changes in bond lengths were observed
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for the Ru-N and Ru-O bonds (Table 3.2), suggesting that substitution of the chlorido
group does not affect the electronics in the bis-chelate to any significant extent. The
phosphorus atom of the PTA group of 3.8 is observed to be in a closer proximity to the
ruthenium centre than the chlorido atom of 2.8 (2.31A˚ vs 2.43A˚, Table 3.2). Two PF6
ions are observed to stabilise the overall +2 charge with no chloride ions present; this
further confirms a complete ion exchange in the synthesis of 3.8. A slight lengthening
of the Ru-N and C=N bonds are observed from 2.8 to 3.8 (Table 3.2), supporting the
conclusion obtained from IR spectroscopic analysis. A small change in the chelation
angle (N-Ru-O, Table 3.2) is observed from 2.8 to 3.8, which suggests the chelate is
unaffected by the change in ligand. No interesting crystal structure characteristics were
observed. The crystallographic data and structure refinement parameters for complex
3.8 is shown in Table 3.3.
Figure 3.10: Ball and stick representation of the molecular structure of 3.8 deter-
mined by single crystal XRD. Hydrogen atoms were omitted for clarity.
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Table 3.2: Selected bond distances (A˚) and angle (°) comparisons for 2.8 and 3.8.
Bond distance (A˚)
Entity 2.8 3.8
Ru-N 2.088(2) 2.098(3)
Ru-O 2.0594(18) 2.060(3)
Ru-Cl 2.4288(8) -
Ru-P - 2.3108(9)
N-C 1.440(3) 1.447(4)
N=C 1.292(3) 1.296(5)
Bond angle (°)
N-Ru-O 88.01(7) 88.33(10)
N-Ru-Cl 85.38(6) -
N-Ru-P - 88.82(8)
O-Ru-Cl 84.61(5) -
O-Ru-P - 81.61(7)
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Table 3.3: Crystallographic data and structure refinement parameters for complex
3.8
Empirical Formula C37H42F3N4OPRu · 2 PF6
Formula Weight (g·mol−1) 1037.73
Temperature (K) 173
Radiation (A˚) 0.71073
Crystal System Monoclinic
Space Group P21/c
Unit Cell dimensions
a (A˚) 19.6879(12)
b (A˚) 13.8716(8)
c (A˚) 17.1161(10)
α (°) 90
β (°) 113.905(1)
γ (°) 90
V (A˚3) 4273.5(4)
Z 4
Density (calc.) (g·cm−1) 1.613
F (000) 2096
Crystal size (mm) 0.11 x 0.11 x 0.18
θmin,max (°) 2.0, 26.4
Data set -24: 24 ; -17: 17 ; -21: 21
Total reflections 61100
Unique reflections 8762
R indices (R1, wR2) 0.0416, 0.1053
Res. Dens. (e A˚−3)min,max -1.10, 1.38
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3.4 Cyclic Voltammetry Study
To gain understanding into the electronic effects of the PTA scaffold (3.1) on the metal,
the electrochemical behaviour of the ferrocenyl PTA complexes (3.13-3.15) was exam-
ined by cyclic voltammetry. The complexes were analysed in acetonitrile solutions (2-5
mM) using 0.1 M n-tetrabutylammonium perchlorate as the background electrolyte. A
scan rate of 100 mV·s−1 was employed with ferrocene used as the external standard. A
comparison of the relevant electrochemical data of 2.14-2.1622 and 3.13-3.15 is given
in Table 3.4. The ferrocene standard exhibited a reversible wave with a half-wave po-
tential of +0.10 V relative to the Ag/Ag+ reference electrode. The ratio of the anodic
and cathodic currents (ipa/ipc) was found to be 0.96, which is close to unity. This
reveals that the Fc/Fc+ couple was a reversible single-electron redox process. This
was further confirmed by the value of ∆Ep = 0.10 V, an acceptable value for the peak
separation indicating a single electron redox process.
Previously, complexes 2.14-2.16 were analysed by Nkoana et al.22 These complexes
demonstrated a reversible single-electron redox wave for the Fc/Fc+ redox couple. In
addition to the Fc/Fc+ couples, irreversible anodic peak potentials for RuII → RuIII,
RhIII → RhIV and IrIII → IrIV were observed in the region of 0.6 to 0.8 V. A loss of the
Fc/Fc+ couples was observed in the voltammograms after substitution of the Cl ligand
for the alkylated benzyl PTA scaffold 3.1 (complexes 3.13-3.15). Two oxidation peak
potentials were observed in the voltammogram of 3.13, at 0.73 V and 0.93 V, with no
corresponding ferrocenium reduction on the return scan. Similarly for complex 3.15,
two irreversible oxidation peaks were observed at -0.13 V and 0.36 V when scanning
from -1.2 V and 1.5 V (A, Figure 3.11). However, changing the scan range to -1.2
V to 0.7 V, a reversible Fc/Fc+ wave with half-potential of 0.32 V was observed (B,
Figure 3.11). As observed for the ferrocene standard, an ipa/ipc value close to unity
confirmed a reversible redox wave. The change in scan range suggests that once the
complex undergoes oxidative stress above a potential of 0.7 V, an additional oxidation
product is formed which cannot be reduced (i.e. product is unstable). No additional
studies have been done to characterise the unstable species further.
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Complex 3.14 was observed to be unstable in the acetonitrile solution and was mon-
itored using peak potentials over a period of 60 minutes at 20 minute intervals. Two
oxidative peaks (a and b, Figure 3.12) were observed in a similar potential range to
3.13 and 3.15. After 20 minutes in the acetonitrile solution these two peaks shifted
closer to each other (B, Figure 3.12). Overlap of the two peak potentials after 40 min-
utes in the acetonitrile solution (ab, C, Figure 3.12) was observed. These temporal
changes in the results suggest decomposition of the complex in the acetonitrile solution.
Based on this result, it can be concluded that substituting the chloride ligand with the
alkylated benzyl PTA scaffold (3.1) interferes with the reversible single-electron redox
processes of the Fc/Fc+ couple.
Table 3.4: Redox potentials (V vs. Ag/Ag+) of compounds 2.14-2.16 from Nkoana et
al.,22 compounds 3.13-3.15 analysed in this study and ferrocene (Fc)a as the standard.
Fe(II)/Fe(III) Other
Comp. Epa Epc E
b
1/2 ∆E
c
1/2 ipc/ipa Epa
2.14 0.36 0.28 0.32 0.19 1.43 0.65
2.15 0.35 0.25 0.30 0.17 1.43 0.77
2.16 0.35 0.27 0.31 0.18 1.17 0.72
3.13 0.73 - - - - 0.93
3.14d -0.04 - - - - 0.64
3.15 0.36 0.28 0.32 0.22 0.96 -0.13
Fc 0.15 0.05 0.10 0.00 0.96 -
a Measured in acetonitrile at a scan rate of 100 mV/s and referenced to Ag/Ag+.
bE1/2 =
Epa + Epc
2
. c∆E1/2 = E1/2(Comp.)− E1/2(Fc).d Initial scan results.
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Figure 3.11: Voltammograms of 3.15 with the scanning potential range of -1.2 to
1.5 V (A) and -1.2 to 0.7 V (B).
Figure 3.12: Voltammograms of 3.14 at 20 (B) and 40 (C) minute intervals from
the initial sampling at (A).
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3.5 Summary
An alkylated PTA scaffold, 3.1, was prepared, characterised and reacted with dimeric
metal precursors, complexes 2.5-2.11 and 2.13-2.16, to yield complexes 3.2-3.15.
Compounds were characterised using NMR (1H, 13C{1H}, 31P{1H}, HSQC, COSY)
and IR spectroscopies, elemental analysis, and high resolution electrospray ionisation
(positive-ion and negative-ion modes) mass spectrometry. The spectroscopic and an-
alytical data obtained for complexes 3.1-3.4 correspond well with the literature.17
Complexes 3.5-3.15 are new compounds and their characterisation data are consistent
with the proposed structures. Single crystals of 3.8 were analysed by X-ray diffraction,
which further confirmed its molecular structure. Cyclic voltammetry studies revealed
no reversible single-electron redox process for the Fc/Fc+ couple of complexes 3.13-
3.15 when tested under the same conditions as the non-PTA analogues (2.14-2.16).
This is in contrast to the non-PTA analogues (2.14-2.16) which were shown to have a
reversible single-electron Fc/Fc+ wave. However, by limiting the scan range (from -1.5
V to +0.7 V), the voltammogram of complex 3.15 revealed a reversible single-electron
Fc/Fc+ couple, with an ipa/ipc value close to unity.
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Preliminary Cytotoxic Evaluation
and Mechanistic Insights
4.1 Introduction
Platinum group metal complexes have shown in recent years to be more favourable to
use over the current platinum-based complexes used in cancer treatments.1–4 Platinum-
based drugs often exhibit potent cytotoxicity against cancer cells, but also against non-
cancerous cells.5 Recently less toxic metals and ligands have been used as alternatives
to the more toxic platinum complexes.6,7 Finding the balance between highly cytotoxic
behaviour in cancerous cells and lower toxicity in non-cancerous cells is imperative for
future drug development. Since the discovery of RAPTA by Dyson and co-workers,8
derivatives of these complexes have shown great promise because some analogues show
increased activity compared to RAPTA.9,10 The prototype RAPTA-C exhibited high
IC50 values (> 200 µM) for the inhibition of glutathione-S-transferase (GST), an en-
zyme responsible for conferring resistance to anticancer drugs.11 However, due to the
low cytotoxicity of the complex against non-cancerous cells, the RAPTA-C moiety has
been incorporated into active compounds.10
One of the drug targets extensively studied with respect to ruthenium complexes, is
DNA. In addition to DNA, ruthenium complexes also interact with other biological ma-
terials.12 Ruthenium protein interactions have been considered as a potential pathway
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to the treatment of cancer.13 Recent studies have suggested this binding is essential for
the antimetastatic behaviour of ruthenium complexes.14 Inhibition of proteins, such as
cathepsin B, GSK-3 and Pim-1 have also been investigated and shown to follow this
pathway.15,16 A high concentration of these proteins are present in tumours, making
them more favourable targets rather than DNA.15 To assist in the binding of metals to
these proteins, researchers have used functional ligands as a method to achieve this.13,17
In the preceding chapters, the synthesis of non-PTA and PTA complexes were reported.
This chapter investigates the anticancer activity of these two families of complexes as
the results could give insight into whether incorporation of the alkylated benzyl PTA
ligand 3.1 is beneficial to enhance cytotoxicity.
4.2 Single Dose Pre-screening
To identify the most active complexes, all of the metal complexes synthesised in this
study were pre-screened for cytotoxicity in the MCF7 carcinoma breast cancer cell
line at a single-dose concentration of 20 µM. This concentration was chosen based
on the National Cancer Institute (NCI, USA) criteria which regard compounds with
IC50 ≤ 20 µg/mL (' 18 µM for the complex with the largest molecular mass synthe-
sised) as having high inhibiting activity.18 Cisplatin was used as the positive control
in this study. To compare the cytotoxicity at the tested concentration, cell viability
was determined using the MTT assay protocol.19 MTT, 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (yellow solution), is a tetrazolium reagent that gets
reduced to a formazan, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylformazan (blue crys-
tal) by dehydrogenases of live cells (Figure 4.1).20 After solubilisation of the formazan,
the concentration of living cells can be determined by measuring the absorbance at 550
nm.20
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Figure 4.1: Conversion of MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) to Formazan (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylformazan).
4.2.1 Cytotoxicity of Metal dimers and Precursors 2.5-2.16
The anticancer data obtained for complexes 2.5-2.16 are illustrated in Figure 4.2.
In general, the ruthenium (2.8, 2.11 and 2.14) and iridium complexes (2.10 and
2.16) showed greater activity than their rhodium (2.9, 2.12 and 2.15) counterparts.
With the exception of 2.12, 2.14 and 2.15, all of the complexes were found to be
more active than the metal dimers (RuD, RhD and IrD). This provides evidence that
the addition of the salicylaldimine group increases the cytotoxicity. Four complexes
(2.8, 2.10, 2.11 and 2.16) displayed greater cytotoxicity than cisplatin at 20 µM
against MCF7 cells, with the most active complex being 2.8. In general, complexes
bearing the trifluoromethane (2.2) and trimethylsilane (2.3) substructure were more
active than complexes with the propyl (2.1) and ferrocenyl (2.4) salicylaldimine ligand.
Compounds 2.2 and 2.3 both have higher ClogP values in comparison to 2.1 and 2.4
(Table 4.1), suggesting the cytotoxicity is linked to the degree of lipophilicity. Since
complexes 2.8, 2.10 and 2.11 showed promise in the pre-screen, these complexes were
taken further to a multi-dose screen (see section 4.3) to determine their IC50 values.
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Figure 4.2: Cell viability was measured after MCF7 cells were treated with 20
µM of the non-PTA complexes 2.5-2.16 and the metal dimers RuD ([RuCl(µ-Cl)(p-
cymene)]2), RhD ([RhCl(µ-Cl)(Cp*)]2) and IrD ([IrCl(µ-Cl)(Cp*)]2) and determined
using the MTT assay.
Table 4.1: Predicted values of ClogPa
Compound ClogP
2.1 2.50
2.2 4.42
2.3 3.89
2.4 3.33b
a LogP values were calculated using MarvinSketch V5.9.4. b Predicted value using method described
in Stringer et. al.21
4.2.2 Cytotoxicity of the PTA scaffold (3.1) and PTA com-
plexes (3.1-3.15)
Compounds 3.1-3.4 showed little to no activity against MCF7 cells at the tested con-
centration. As these compounds are water soluble, a pre-screen of 3.1-3.4 was done in
medium only (no DMSO was used to solubilise the compounds) with little change to
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the data obtained when DMSO was used to solubilise the compound (Figure 4.3). This
data shows that there is very little effect on the cell viability when DMSO was used in
the assay. In order to compare the results of that obtained for compounds 2.5-2.16,
all of the biological studies for compounds 3.1-3.15 were performed using DMSO to
solubilise the compounds. The data for complexes 3.1-3.15 are given in Figure 4.4.
Complexes 3.2-3.15 were found to be less active than the non-PTA complexes at the
same concentration (comparing the data in Figure 4.2 and Figure 4.4). These results
strongly suggest that addition of the PTA moiety suppresses the activity. This may
be due to the high solubility of these compounds in aqueous media which prevents the
complex from passing through the cell membrane and preventing intracellular accu-
mulation. As discussed in the previous section, the lipophilicity plays a key role in
the activity of the complex. The lipophilicity of the PTA complexes are much lower
than the preceding complexes due to the addition of 3.1, which has a ClogP value of
-0.99. Although not as active as their non-PTA counterparts, complexes 3.7 and 3.13
are comparable in activity to cisplatin at the tested concentration, but did not show
comparable activity to 2.8, 2.10 and 2.11 and therefore were not evaluated in the
multi-dose screen.
Figure 4.3: Comparison of the effect on MCF7 cell viability of 20 µM of complexes
3.1-3.4 dissolved in either DMSO or H2O determined using the MTT assay.
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Figure 4.4: Cell viability of MCF7 cells obtained after treatment with PTA complexes
3.1-3.15 at 20 µM drug concentration.
4.3 Multi-dose screen of 2.8, 2.10, and 2.11
To determine the IC50 values of compounds 2.8, 2.10 and 2.11 in MCF7 breast cancer
cells, a multi-dose screen was conducted at 5, 10, 15, 20 and 25 µM concentrations. The
experiments were performed on three different occasions in quadruplicate and the dose
response curves and IC50 values are represented in Figure 4.5 and Table 4.2, respec-
tively. As observed in the pre-screen, 2.8 was the most active complex, with an IC50
value of 16.83 µM. Changing from the ruthenium p-cymene (2.8) to iridium Cp* (2.10)
moiety results in an IC50 of 20.75 µM. This suggests that the metal fragment plays
an important role in the cytotoxicity exhibited in MCF7 cells. In changing the ligand
from trifluoromethane (2.8) to trimethylsilane (2.11) in the ruthenium complexes, a
slight drop in cytotoxicity was also observed (16.83 to 19.48 µM, respectively). The
increase in cytotoxicity observed for 2.8 is consistent with reports that fluorine contain-
ing compounds show great promise as anticancer agents.22 Compound 2.8 bears the
ligand with the greatest ClogP value (2.2, see Table 4.1), which could suggest greater
accumulation in the cells and therefore more interaction with intracellular targets. To
evaluate their selectivity, the compounds were also tested against non-cancerous Chi-
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nese hamster ovarian (CHO) cells. Complexes 2.10 and 2.11 showed lower toxicity
in the CHO cells than in the MCF7 cell line, with IC50 values above 80 µM observed,
which is considered to be inactive.18 Complex 2.8 was found to be more active in the
CHO cells (IC50 = 5.67 µM) than in the MCF7 cells (IC50 = 16.83 µM). Calculating
the selectivity index (SI) of these complexes can give insight into which cell line the
complex has greater selectivity to inhibit growth. The selectivity index shows that
complex 2.8 has a greater selectivity for non-tumorous cells (SI = 0.34). This suggests
that complex 2.8 may not be a suitable candidate for further testing as a potential
anticancer drug. Larger selectivity indices were obtained for complexes 2.10 and 2.11
(SI > 4), suggesting that these complexes may be more selective towards cancerous
cells and maybe be potential candidates for further testing.
Figure 4.5: Dose-response curves of cell viability obtained by MTT assays for MCF7
cells treated with complexes 2.8, 2.10 and 2.11.
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Table 4.2: IC50 values (with standard error (SE)) and selectivity indices (SI) of 2.8,
2.10 and 2.11 against the MCF7 breast cancer cell line and the Chinese hamster
ovarian (CHO) cell line.
Complex MCF7 (IC50±SE, µM) CHO (IC50±SE, µM) SIa
2.8 16.83 ± 1.17 5.67 ± 0.59 0.34
2.10 20.75 ± 1.32 95.71 ± 6.05 4.61
2.11 19.48 ± 1.25 84.00 ± 17.70 4.31
aSelectivity Index: IC50-CHO/IC50-MCF7.
4.4 Stability and Insight into the Mechanism of Ac-
tion
Determining the stability of compounds in blood and aqueous media is important for
identifying potential drug candidates.23 The stability of all biologically active com-
pounds should be investigated in order to elucidate the reason for their activity. In
some cases the candidate breaks down (depending on the environment) resulting in the
formation of an active complex. In other cases the compound remains intact.24 Two
of the most active complexes in the pre-screen (2.8 and 2.10) were monitored using
1H NMR spectroscopy in DMSO-d6 for 48 hours at 37 °C (MTT assay temperature).
To gain insight into the possible species found in media and serum, compounds were
monitored in a mixture of 1:1 v/v % DMSO-d6:H2O and 150 mM NaCl(aq) in DMSO-
d6 (1:1 v/v % DMSO:H2O) under the same conditions.
25 The reason for monitoring
the effect of having NaCl present at high concentrations is to minimise any hydrolysis
from occurring. As the most active complex against both the MCF7 and CHO cell
lines was 2.8, its interaction with guanosine 5′-monophosphate disodium salt hydrate
(GMP), a RNA monomer, was monitored by 1H NMR spectroscopy in a 1:1 v/v %
DMSO-d6:H2O mixture.
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4.4.1 Solvent Stability
The stability of complex 2.8 was investigated by 1H NMR spectroscopy in DMSO-
d6 to simulate the chemical environment prior to cell viability studies. The
1H NMR
spectrum shows after 24 hours, the formation of a new species (0 to 24 hrs, Figure 4.6).
Signals for the salicylaldimine group (signals 8-11 and 13, Figure 4.6) are observed to
double up, evidence that a new species had formed. After 24 hours, the imine resonance
of 2.8 (6, Figure 4.6) was observed as two signals. No significant change from 24
to 48 hours was observed, suggesting the formation of the new species had reached
equilibrium with 2.8 within 24 hours. In contrast to the ruthenium case, 2.10 showed
greater stability in DMSO-d6 under these conditions. The stacked
1H NMR spectra of
2.10 in DMSO-d6 at 24 hour intervals are shown in Figure 4.7. No additional signals
were observed within the 48 hour testing period (Figure 4.6). Integration of the signals
after 48 hours in DMSO for 2.10 (Figure 4.7) is consistent with the reported data in
Chapters 2 and 6 (i.e. no decomposition observed).
Figure 4.6: 1H NMR spectra comparison of 2.8 over a 48 hour period in DMSO-d6
sampling taken at 24 hour intervals. Signals labelled with an ∗ are from the new species
formed during the experiment.
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Figure 4.7: 1H NMR spectra comparison of 2.10 over a 48 hour period in DMSO-d6
sampling taken at 24 hour intervals.
The results obtained in this study suggests that the ruthenium complex (2.8) undergoes
solvation and the resulting complex might be responsible for the cytotoxicity observed
in the MTT assay. Contrast to this, the iridium complex (2.10) does not undergo
solvation (remains intact) which suggest that this complex is possibly generating the
cytotoxicity observed.
4.4.2 Aqueous Stability
The behaviour of the afore-mentioned complexes were also studied in partial aqueous
solutions to mimic biological conditions. NaCl was used to mimic the salt concentration
outside of cells in the body.25 Complex 2.8 was analysed for its aqueous stability. A
shift in the imine resonance was observed when both a high concentration of H2O
and NaCl is present (signal 6, Figure 4.8), suggesting there is a change in the species
present in solution. Doubling of the aromatic and imine signals (3-11, Figure 4.8) are
not observed in the aqueous-media spectra (signals 3-11 of [C] and [D], Figure 4.8),
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suggesting the presence of a single species in solution. A downfield shift, as well as a
change in the splitting pattern of the p-cymene proton resonances (following 13 from
A to D, Figure 4.8), is observed which strongly suggests substitution of the labile Cl
ligand with DMSO-d6 or H2O, as these are high in concentration. Since the biological
assay medium contains a range of salts and is mainly constituted of H2O, there is a high
likelihood that the active complex is different to the complex that is initially isolated.
Figure 4.8: 1H NMR spectra comparison of 2.8 at 0 and 48 hours after sample
preparation in DMSO-d6.
Complex 2.10, though stable in DMSO, was found to form a new species in the different
mixtures of DMSO and H2O. Cleavage of the imine bond was observed when high
concentrations of H2O were present, supported by the appearance of the CHO signal
in the 1H NMR spectra [C] and [D] (Figure 4.9). The Cp* signal was observed at
1.25 and 1.18 ppm for the DMSO-d6:H2O and 150 mM NaCl(aq) samples, respectively,
which differs from the DMSO-d6 sample at 1.23 ppm (signal 13, [B], Figure 4.9). A
doublet is observed for the Cp* (signal 13*, Figure 4.9) suggesting that the active
species may not be the complex isolated initially.
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(i)
(ii)
Figure 4.9: (i) 1H NMR spectra comparison of 2.10 at 0 and 48 hours after sample
preparation in DMSO-d6 mixtures. (ii) Expanded region of (i) between 0.0-3.0 ppm.
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4.4.3 Binding Study: 5′-GMP with 2.8
Guanosine 5′-monophosphate disodium (5′-GMP) is a simplistic model used to study
possible nucleotide interaction of complexes. Complex 2.8, the most active complex,
was reacted with 5′-GMP in a DMSO-d6:H2O mixture, at 37 °C over 48 hours, to
understand the interactions with RNA/DNA. Free GMP was studied under the same
conditions and was observed to have no change from the initial 1H NMR spectrum.
Ruthenium complexes have been reported to bind to single stranded DNA via nitrogen
donor atoms from guanosine, in particular the N7 atom.9,12,26 Complex 2.8 was anal-
ysed for its GMP binding affinity using 1H NMR spectroscopy. A distinctive shift in
the proton signals of the arene coordinated to the metal centre (signals 13, 14 and 19,
Figure 4.10), indicating a change in the metal centre environment. The aqua product
of the complex observed in the aqueous stability study (Figure 4.8) was observed in the
2.8-GMP mixture, however this product is minor (see signals 6 and 13 in Figure 4.10).
A shift of the proton resonance at 8.0 ppm (a, Figure 4.10) strongly supports the co-
ordination of the complex at the N-7 atom. This result is consistent with the reported
shift in the 5′-GMP proton signals for ruthenium-GMP products.9 This suggests the
reason why 2.8 is very active against both cell lines tested, as this mechanism would
not be specific to cancerous cells only. The binding of 2.8 and GMP, and the aqua
species formed suggests that an aqua species is formed before the nucleotide binds.9
A similar mechanism is observed for cisplatin5, which could explain the high levels of
toxicity towards healthy cells.
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Figure 4.10: 1H NMR spectra comparison of 2.8 and GMP after 48 hours in
DMSO:H2O mixtures.
4.5 Summary
The cytotoxicity of compounds 2.5-2.16, 3.1-3.15, as well as the dimeric metal pre-
cursors were evaluated against the MCF7 breast carcinoma cell line. Complexes 2.8,
2.10 and 2.11 exhibited the highest activity in this cell line, with IC50 values of 16.83,
20.75 and 19.48 µM observed, respectively. The activity of these complexes can be
linked to the lipophilicity of their ligands. The greater the ClogP value of the ligand
of the complex, the greater the cytotoxicity observed. The most active complexes were
also evaluated against the Chinese hamster ovarian (CHO) cell line as a representative
of normal, healthy cells. Complex 2.8 was highly active against the CHO cells (IC50
= 5.67 µM), while the other two complexes (2.10 and 2.11) displayed lower toxicity
(IC50 > 80 µM).
A possible mechanism of action for 2.8 and 2.10 was investigated using 1H NMR spec-
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troscopy in DMSO-d6, DMSO:H2O and NaCl(aq). Doubling of signals in the spectrum
of complex 2.8 suggested low stability in DMSO-d6, however complex 2.10 was found
to be stable. Aqua and DMSO species of 2.8 and 2.10 were observed after 48 hours in
DMSO-d6:H2O. Complex 2.8 showed evidence of binding to 5
′-GMP, suggesting a pos-
sible mechanism of action similar to cisplatin and a reason for the cytotoxic behaviour
against healthy cells.
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Conclusion and Future Prospects
5.1 Overall Summary and Conclusions
In this study various salicylaldimine complexes of ruthenium, rhodium and iridium have
been synthesised and fully characterised using spectroscopic and analytical techniques
such as 1D (1H, 13C{1H}, 31P{1H}) and 2D (COSY, HSQC) NMR spectroscopy, IR
spectroscopy and mass spectrometry. Most of the complexes that are reported here
have been synthesised for the first time to the best of our knowledge.
In order to afford the complexes, four salicylaldimine ligands (2.1-2.4) were prepared
via a Schiff-base condensation reaction from commercially available reagents. Charac-
terisation of these ligands revealed that the proposed compounds were obtained. These
ligands were isolated in high yields. The salicylaldimine ligands were then complexed
using [RuCl(µ-Cl)(p-cymene)]2, [RhCl(µ-Cl)(Cp*)]2 or [IrCl(µ-Cl)(Cp*)]2 via a bridge-
splitting reaction, after deprotonation of the ligand using a suitable base, to yield a
series of neutral salicylaldimine PGM complexes (2.5-2.16). Complexes 2.8-2.13 are
new and have been fully characterised. The spectroscopic and analytical data revealed
that the ligand coordinates to the metal in a (N,O)-bidentate fashion. For complexes
2.5-2.16 an upfield shift in the imine proton resonance in the 1H NMR spectra from
ligand to complex is observed, as well as a downfield shift of the C-O-M carbon reso-
nance in the 13C{1H} NMR spectra. A shift of the imine stretching vibration to lower
wavenumber further confirmed the (N,O)-bidentate coordination mode. Complexation
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was further confirmed by the molecular structures obtained for 2.8-2.10 using X-ray
diffraction. A pseudo-tetrahedral geometry was observed about the metal centre for
these complexes, indicative of a piano-stool structure.
Once the neutral complexes had been synthesised, a series of PTA-containing complexes
were prepared. Reaction of [RuCl(µ-Cl)(p-cymene)]2, [RhCl(µ-Cl)(Cp*)]2, [IrCl(µ-
Cl)(Cp*)]2, 2.5-2.11 and 2.13-2.16 with an alkylated PTA scaffold (3.1) afforded
complexes 3.2-3.15. Complexes 3.2-3.7 and 3.11-3.13 were isolated as chloride salts
and were observed to be hygroscopic. Complexes 3.8-3.10, 3.14 and 3.15 were iso-
lated as PF6 salts, since decomposition of the chloride analogues of these complexes
was observed. Complexes 3.5-3.15 are new compounds and were fully characterised.
A significant downfield shift of the phosphorus resonance of the PTA is observed upon
coordination to the metal centre, suggesting the synthesis of the target complexes. The
molecular structure of 3.8 was obtained and further confirmed the proposed structure.
The molecular structure revealed that the phosphorus atom of the PTA scaffold coor-
dinates to the metal centre, and substitutes the chlorido ligand (comparing 2.8 and
3.8). The molecular structure also shows that the three-legged piano-stool geometry
was retained upon complexation with 3.1.
All of the complexes, as well as 3.1 and the dimeric metal precursors, were screened for
potential anticancer activity in MCF7 breast cancer cells in vitro. The salicylaldimine
complexes 2.8, 2.10 and 2.11 exhibit enhanced activity in comparison to cisplatin at
the 20 µM tested concentration. For multidose screening, IC50 values below 21 µM
were observed. Compounds containing PTA (3.1-3.15) and the dimeric precursors
did not display good activity at the tested concentration in comparison to cisplatin.
Complexes 2.8, 2.10 and 2.11 were also screened against Chinese hamster ovarian
cells (CHO) to gauge selectivity. Complex 2.8 showed cytotoxicity in the CHO cells,
suggesting that the complex was not very selective towards cancer cells (SI = 0.34),
whereas 2.10 and 2.11 were more selective towards MCF7 (SI > 4). To understand the
possible reason for the cytotoxicity, binding studies of 2.8 and a nucleotide, guanosine
5′-monophosphate disodium (5′-GMP) were conducted. Binding of the complex to the
nucleotide was observed, suggesting a similar mechanism of action to cisplatin (i.e. it
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interacts with the N7 atom of guanine, which is similar in structure to 5′-GMP).
5.2 Future Prospects
Based on our findings in this study, the following adjustments could be made to enhance
the biological activity of the complexes reported here.
5.2.1 Further Mechanistic Insights
Compounds 2.8, 2.10 and 2.11 exhibited good activity and a preliminary investiga-
tion into a possible mechanism of action was conducted. The activity observed for
some compounds is promising, but certain modifications could be made to increase
the potency as well as selectivity. Once promising compounds are afforded, we must
understand their interactions with the biomolecules located inside the cells. Additional
tests, such as Western-Blot analysis and DNA binding studies, can give additional in-
formation of the binding affinity to RNA or DNA. This would also give insight into how
the complex interacts (e.g. pi-pi stacking, coordination) with nucleic acids. Additional
studies (e.g. viscosity, UV absorption, DNA denaturing, protein binding) might also
give further insights into the mechanism of action. Based on the data obtained from
the tests, modification of either the ligand or metal could change or strengthen inter-
actions with biomolecules. Screening against other cancer cell lines (e.g. A2780 and
A2780cis, HEK, MDA-MB-231) would give additional information into the biological
profile of these complexes, as well as the type of cancer cell lines most susceptible to
the complexes.
5.2.2 Modifications to Enhance Activity
The metal appears to have a significant effect on the activity in this study. Most of the
rhodium complexes tested exhibited very poor activity in comparison to the ruthenium
and iridium complexes. Two of the three most active complexes have a ruthenium
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centre; however, 2.8 had low selectivity towards cancerous cells. The iridium complex,
2.10, exhibits enhanced activity as well as some selectivity towards cancerous cells.
This suggests strongly that iridium(III) complexes should be researched in greater
depth to determine whether this metal is more effective than others and could present
a different approach towards the treatment of this disease.
Some ligand types are observed to show favourable effects on the biological activity of
the complexes. Several ligands appear to increase the cellular uptake of the complex,
which could allow for better interactions with biomolecules. It was observed in this
study that an increase in the lipophilicity of the ligand yielded more potent anticancer
activity, as observed with complexes containing 2.2 and 2.3. Further increasing the
lipophilicity by adding more fluorine groups or a fatty acid, might increase the activity.
A balance between lipo- and hydrophilicity of the drug candidates is very important.
The use of alkylated PTA derivatives did not result in an increase in the activity of the
salicylaldimine complexes 2.5-2.16. A less hydrophilic approach could be implemented
to help find the optimal balance. A common technique is to use solvated complexes.
Using DMSO or aqua ligands instead of chlorido ligands (as most chlorido groups
usually get displaced to form aqua or solvated complexes) would aid in the solubility.
This would help with the hydrophilic-lipophilic crossover, as well as in any mechanistic
pathways. Figure 5.1 is a proposed structure that incorporates the suggested changes
to the complexes exhibiting the most promising cytotoxic responses. It is suggested
that the investigation of the synthesis and properties of such compounds would provide
a promising avenue to extend this study for future research.
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Figure 5.1: Proposed structure for modification to active complexes.
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Experimental
6.1 General Details
Reagents were purchased from Sigma-Aldrich or Merck and were used without further
purification. Solvents were purchased from KIMIX and were dried using molecular
sieves. Nuclear magnetic resonance (NMR) spectra were recorded on a Bruker Top-
spin GmbH (1H at 400.22 MHz, 13C{1H} at 100.65 MHz, 19F{1H} at 376.58 MHz,
31P{1H} at 162.01 MHz) or a Varian Mercury 300 (1H at 300.08 MHz) spectrom-
eter, with a Bruker Biospin GmbH casing and sample injector at 30 °C. Chemical
shifts were reported using tetramethylsilane (TMS) as the internal standard. Infrared
(IR) absorptions were measured on a Perkin-Elmer Spectrum One FT-IR spectrom-
eter using attenuated total reflection (ATR) in the solid state. Elemental analysis
was carried out using a Fissions EA 110 CHNS elemental analyser. Electron impact
(EI) mass spectrometry was carried out on a JEOL GCmate II mass spectrometer
(2.1-2.7 and 2.14-2.16). Electrospray ionisation (ESI) mass spectrometry was carried
out on a Waters API Quattro instrument in the positive-ion (2.8-2.13 and 3.1-3.15)
and negative-ion (3.5-3.15) modes. Melting points were determined using a Bu¨chi
melting point B-540 apparatus and are uncorrected. The dimeric precursors ([RuCl(µ-
Cl)(p-cymene)]2, [RhCl(µ-Cl)(Cp*)]2 and [IrCl(µ-Cl)(Cp*)]2) were synthesised using
published methods.1,2
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6.2 (N,O)-Salicylaldimine ligands (2.1-2.4)
6.2.1 Propylsalicylaldimine3 (2.1)
n-Propylamine (0.363 g, 6.14 mmol) and salicylaldehyde (0.690 g, 5.65 mmol) were
added to a stirring solution of diethyl ether, and the resulting yellow solution was left
to react for 18 hours. The ether mixture was washed with water (3 x 15 mL), the
organic fraction collected and dried using anhydrous magnesium sulfate. The drying
agent was removed by gravity filtration and the solvent removed under reduced pressure
to yield the product (2.1) as a yellow oil. Yield: 0.845 g (91.6 %). 1H NMR (400
MHz, CDCl3) : δH(ppm) = 1.00 (3H, t,
3J = 7.4 Hz, H-1), 1.74 (2H, m, H-2), 3.56
(2H, td, 3J = 6.8 Hz, 4J = 1.2 Hz, H-3), 6.88 (1H, td, 3J = 7.5 Hz, 4J = 1.1 Hz, H-8),
6.97-6.99 (1H, m , H-6), 7.23-7.26 (1H, m, H-9), 7.28-7.31 (1H, m, H-7), 8.33 (1H, m,
H-4), 13.66 (1H, s, OH). 13C{1H} NMR (100 MHz, CDCl3) : δC(ppm) = 11.59
(C-1), 23.99 (C-2), 61.16 (C-3), 116.95 (C-6), 118.27 (C-8), 118.77 (C-5), 131.01 (C-9),
131.92 (C-7), 161.37 (C-10), 164.46 (C-4). IR (ATR): νmax/cm
−1 = 1633 (C=N).
EI-MS m/z 163.0042 (100%, [M]+). Analysis Calc. for C10H13NO: C, 73.59; H,
8.03; N, 8.58. Found: C, 73.66; H, 8.03; N, 8.26.
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6.2.2 N -(p-Trifluoromethyl)phenylsalicylaldimine4 (2.2)
Salicylaldehyde (0.460 g, 3.77 mmol) and 4-(trifluoromethyl)aniline (0.614 g, 3.98
mmol) were added to diethyl ether (2 mL) and the resulting yellow suspension was
left to react for 16 hours. The suspension was diluted with 20 mL n-pentane and the
yellow solid (2.2) filtered. Yield: 0.920 g (92.1 %). Melting Point: 198-200 °C. 1H
NMR (400 MHz, CDCl3): δH (ppm) = 6.98 (1H, t,
3J = 7.2 Hz, H-10), 7.05-7.07
(1H, m, H-8), 7.36 (2H, d, 3J = 8.3 Hz, H-3), 7.42-7.45 (2H, m, H-9 and H-11), 7.77
(2H, d, 3J = 8.3 Hz, H-4), 8.68 (1H, s, H-6), 12.80 (1H, br s, OH). 13C{1H} NMR
(100 MHz, CDCl3): δC(ppm) = 117.44 (C-8), 118.93 (C-7), 119.33 (C-10), 121.46
(C-4), 124.89 (q, 1JC−F = 272.0 Hz, C-1), 126.64 (q, 3JC−F = 3.7 Hz, C-3), 128.74
(q, 2JC−F = 32.5 Hz, C-2), 132.68 (C-9), 133.90 (C-11), 151.70 (C-5), 161.25 (C-12),
164.48 (C-6). 19F{1H} NMR (376 MHz, CDCl3): δF (ppm) = -62.22 (s). IR
(ATR): νmax/cm
−1 = 1623 (C=N). EI-MS m/z 265.007 (100%, [M]+). Analysis
Calc. for C14H10F3NO: C, 63.40; H, 3.80; N, 5.28. Found: C, 63.05; H, 3.36; N,
5.05.
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6.2.3 N -(3-Trimethylsilyl)propylsalicylaldimine (2.3)
Salicylaldehyde (0.437 g, 3.58 mmol) and 3-aminopropyltrimethylsilane (0.548 g, 4.17
mmol) were stirred in diethyl ether under an inert atmosphere for 16 hours. The
resulting yellow solution was then washed with water (3 x 15 mL) to remove the excess
amine. The organic fraction was collected, dried using anhydrous magnesium sulfate
and the solvent removed to yield a yellow oil after gravity filtration of the drying agent.
The oil (2.3) was dried in vacuo. Yield: 0.783 g (93.2 %). 1H NMR (400 MHz,
CDCl3): δH(ppm) = 0.02 (9H, s, H-1), 0.53-0.59 (2H, m, H-2), 1.66-1.76 (2H, m,
H-3), 3.60 (2H, t, 3J = 7.4 Hz, H-4), 6.89 (1H, t, 3J = 7.4 Hz, H-9), 6.99 (1H, d, 3J =
8.3 Hz, H-7), 7.26-7.35 (2H, m, H-8 and H-10), 8.35 (1H, s, H-5), 13.70 (1H, s, OH).
13C{1H} NMR (100 MHz, CDCl3): δC(ppm) = -1.79 (C-1), 14.14 (C-2), 25.51
(C-3), 62.68 (C-4), 117.03 (C-7), 118.30 (C-9), 118.81 (C-6), 131.04 (C-10), 131.97 (C-
8), 161.47 (C-11), 164.42 (C-5). EI-MS m/z 235.1259 (100%, [M]+). Analysis Calc.
for C13H21NOSi: C, 66.33; H, 8.99; N, 5.95. Found: C, 66.31; H, 9.20; N, 5.96.
6.2.4 Salicylaldehyde hydrazone (L1)
A solution of salicylaldehyde (3.68 g, 31.3 mmol) in ethanol (40 mL) was added to a
stirring solution of hydrazine hydrate (3.0 mL) in ethanol (70 mL) over 65 minutes.
The clear solution was stirred for an additional 5 minutes before being concentrated
to 20 mL and cooled to aid the crystallisation of the product, L1. The white crystals
were isolated by filtration and dried in vacuo. Yield: 1.47 g (34.5 %). 1H NMR (400
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MHz, CDCl3): δH (ppm) = 5.44 (2H, br s, NH2), 6.86 (1H, t,
3J = 7.5 Hz, H-5),
6.94 (1H, d, 3J = 8.2 Hz, H-3), 7.09-7.11 (1H, m, H-6), 7.18-7.23 (1H, m, H-4), 7.87
(1H, s, H-1), 11.04 (1H, s, OH). IR (ATR): νmax/cm
−1 = 1615 (C=N), 3383 (NH2).
EI-MS m/z 136.04 (100%, [M]+). Analysis Calc. for C7H8N2O: C, 61.75; H, 5.92;
N, 20.58. Found: C, 61.65; H, 5.69; N, 20.56.
6.2.5 Ferrocenyl salicylaldimine5 (2.4)
To a stirring solution of salicylaldehyde hydrazone, L1 (0.677 g, 5.00 mmol) in methanol
(30 mL), ferrocenecarboxaldehyde (1.07 g, 5.02 mmol) in methanol was added dropwise.
The red solution was stirred for 16 hours at room temperature. The resulting red
precipitate (2.4) was isolated by vacuum filtration, washed with cold methanol and
dried in vacuo. Yield: 0.944 g (74.9%). Melting Point: 128-129 °C. 1H NMR (300
MHz, CDCl3): δH (ppm) = 4.25 (5H, s, H-1), 4.51 (2H, br s, H-2), 4.74 (2H, br s,
H-3), 6.94 (1H, t, 3J = 7.4 Hz, H-10), 7.03 (1H, d, 3J = 8.1 Hz, H-8), 7.30 – 7.38 (2H,
m, H-11 and H-9), 8.54 (1H, s, H-5), 8.70 (1H, s, H-6), 11.84 (1H, s, OH). 13C{1H}
NMR (100 MHz, CDCl3): δC(ppm) = 68.99 (C-2), 69.45 (C-1), 71.17 (C-4),71.51
(C-3), 116.86 (C-9), 117.97 (C-7), 119.38 (C-8), 132.00 (C-11), 132.31 (C-10), 159.54
(C-12), 162.55 (C-6), 163.75 (C-5). IR (ATR): νmax/cm
−1 = 1586 (C=N), 1618
(C=N). EI-MS m/z 332.05 ([M]+, 100%). Analysis Calc. for C18H16FeN2O: C,
65.08; H, 4.86; N, 8.43. Found: C, 64.50; H, 4.85; N, 8.13.
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6.3 (N,O)-salicylaldimine metal complexes (2.5-2.16)
6.3.1 General Synthesis
(i) Synthesis of 2.5-2.10 and 2.12
Compounds 2.1, 2.2 or 2.3 and triethylamine were reacted in dichloromethane for
60 minutes. To the yellow solution, [RuCl(µ-Cl)(p-cymene)]2, [RhCl(µ-Cl)(Cp*)]2 or
[IrCl(µ-Cl)(Cp*)]2 was added and stirred for 18 hours. The solution was then washed
with water (3 x 15 mL) in a separating funnel, and the organic fraction collected
and dried using anhydrous magnesium sulfate. After removal of the drying agent by
filtration, the solvent was removed and the residue taken up in a minimal amount of
dichloromethane, to which diethyl ether was added to precipitate the desired complex.
(ii) Synthesis of 2.11 and 2.13
[RuCl(µ-Cl)(p-cymene)]2 or [IrCl(µ-Cl)(Cp*)]2 was added to a stirring solution of tri-
ethylamine and 2.3 in diethyl ether and was stirred for 18 hours at room temperature.
The excess dimer and triethylammonium chloride that formed during the reaction were
filtered off and a red or orange solution was obtained. The solvent was removed in vacuo
and the residue washed with n-pentane to yield the desired complexes.
(iii) Synthesis of 2.14-2.16
Triethylamine and 2.4 were stirred in ethanol for 30 minutes. The resulting red mixture
was diluted with ethanol (10 mL) before [RuCl(µ-Cl)(p-cymene)]2, [RhCl(µ-Cl)(Cp*)]2
or [IrCl(µ-Cl)(Cp*)]2 was added to the reaction mixture and further stirred for 18
hours. The desired product precipitated and was isolated by vacuum filtration as a red
or orange amorphous powder. The powder was washed with n-pentane (3 x 10 mL)
and dried in vacuo.
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6.3.1.1 Ruthenium propylsalicylaldimine complex3 (2.5)
2.1 (0.0720 g, 0.441 mmol) and triethylamine (0.1 mL, 0.717 mmol) were reacted with
[RuCl(µ-Cl)(p-cymene)]2 (0.102 g, 0.167 mmol). Complex 2.5 was isolated as a brown
powder. Yield: 0.0884 g (61.3 %). Melting Point: 189°C to dec. with melting. 1H
NMR (400 MHz, CDCl3): δH (ppm) = 1.03 (3H, t,
3J = 7.4 Hz, H-1), 1.14 (3H, d,
3J = 6.6 Hz, H-11), 1.24 (3H, d, 3J = 6.6 Hz, H-11), 1.96-1.98 (1H, m, H-2), 1.99-2.07
(1H, m, H-2), 2.21 (3H, s, H-17), 2.78 (1H, sept, 3J = 6.9 Hz, H-12), 3.99 (1H, m,
H-3), 4.20 (1H, m, H-3), 5.04 (1H, m, H-15), 5.38 (1H, m, H-15), 5.40 (2H, m, H-14),
6.40 (1H, t, 3J = 7.2 Hz, H-8), 6.90 (1H, m, H-6), 6.95 (1H, m, H-9), 7.15 (1H, m,
H-7), 7.67 (1H, s, H-4). 13C{1H} NMR (100 MHz, CDCl3) : δC(ppm) = 11.56
(C-1), 18.52 (C-17), 21.67 (C-11), 22.68 (C-11), 24.36 (C-2), 30.51 (C-12), 71.07 (C-3),
80.24 (C-15), 81.90 (C-15), 83.75 (C-14), 97.37 (C-16), 101.60 (C-13), 114.01 (C-8),
119.31 (C-5), 122.30 (C-9), 134.28 (C-6), 134.49 (C-7), 163.47 (C-4), 165.04 (C-10).
IR (ATR): νmax/cm
−1 = 1624 (C=N). EI-MS m/z 433.07 (100%, [M]+). Analysis
Calc. for C20H26ClNORu: C, 55.48; H, 6.05; N, 3.24. Found: C, 55.13; H, 6.25; N,
3.01.
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6.3.1.2 Rhodium propylsalicylaldimine complex6 (2.6)
2.1 (0.0711 g, 0.436 mmol) and triethylamine (0.0726 g, 0.717 mmol) were reacted with
[RhCl(µ-Cl)(Cp*)]2 (0.100 g, 0.162 mmol). Complex 2.6 was isloated as a red powder.
Yield: 0.0650 g (46.1 %). Melting Point: 216°C to dec. with melting. 1H NMR
(400 MHz, CDCl3): δH (ppm) = 0.98 (3H, t,
3J = 7.4 Hz, H-1), 1.55 (15H, s, H-12),
1.84-1.86 (1H, m, H-2), 2.09-2.17 (1H, m, H-2), 3.70-3.90 (1H, m, H-3), 3.90-4.15 (1H,
m, H-3), 6.44 (1H, t, 3J = 7.2 Hz, H-8), 6.94-6.96 (1H, m, H-6), 7.01 (1H, dd, 3J = 7.8
Hz, 4J = 1.8 Hz, H-9), 7.15-7.19 (1H, m, H-7), 7.80 (1H, m, H-4). 13C{1H} NMR
(100 MHz, CDCl3): δC(ppm) = 8.69 (C-12), 11.53 (C-1), 23.90 (C-2), 65.63 (C-3),
92.75 (d, 1JC−Rh = 8.1 Hz, C-11), 114.10 (C-8), 121.93 (C-5), 123.88 (C-6), 133.79 (C-
9), 134.02 (C-7), 162.47 (C-4), 166.76 (C-10). IR (ATR): νmax/cm
−1 = 1627 (C=N).
EI-MS m/z 434.88 (60%, [M]+). Analysis Calc. for C20H27ClNORh: C, 55.12;
H, 6.25; N, 3.21. Found: C, 54.95; H, 6.09; N, 2.90.
6.3.1.3 Iridium propylsalicylaldimine complex6 (2.7)
2.1 (0.0557 g, 0.341 mmol) and triethylamine (0.1 mL, 0.717 mmol) were reacted
with [IrCl(µ-Cl)(Cp*)]2 (0.0998 g, 0.125 mmol). Complex 2.7 was isolated as a yellow
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powder. Yield: 0.0251 g (19.0 %). Melting Point: 209°C to dec. with melting.
1H NMR (400 MHz, CDCl3): δH (ppm) = 0.99 (3H, t,
3J = 7.3 Hz, H-1), 1.52
(15H, s, H-12), 1.87-2.17 (2H, m, H-2), 3.85-4.09 (2H, m, H-3), 6.42 (1H, t, 3J =
7.3 Hz, H-8), 6.88-6.90 (1H, m, H-6), 7.02 (1H, dd, 3J = 7.7 Hz, 4J = 1.8 Hz, H-9),
7.22-7.24 (1H, m, H-7), 7.75 (1H, s, H-4). 13C{1H} NMR (100 MHz, CDCl3):
δC(ppm) = 8.85 (C-12), 11.44 (C-1), 23.98 (C-2), 68.39 (C-3), 84.70 (C-11), 114.84
(C-8), 121.88 (C-5), 122.77 (C-6), 133.17 (C-9), 134.06 (C-7), 159.82 (C-4), 165.22
(C-10). IR (ATR): νmax/cm
−1 = 1625 (C=N). EI-MS m/z 525.14 (95%, [M]+).
Analysis Calc. C20H27ClIrNO: C, 45.75; H, 5.18; N, 2.67. Found: C, 45.47; H,
5.05; N, 2.41.
6.3.1.4 Ruthenium trifluoro complex (2.8)
2.2 (0.0875 g, 0.330 mmol) and triethylamine (0.1 mL, 0.717 mmol) were reacted with
[RuCl(µ-Cl)(p-cymene)]2 (0.101 g, 0.164 mmol). Complex 2.8 was isolated as a brown
powder. Yield: 0.0833 g (47.4%). Melting Point: 226°C to dec. with melting. 1H
NMR (400 MHz, CDCl3): δH (ppm) = 1.14 (3H, d,
3J = 6.8 Hz, H-13), 1.19 (3H,
d, 3J = 6.8 Hz, H-13), 2.13 (3H, s, H-19), 2.64 (1H, sept, 3J = 6.8 Hz, H-14), 4.25
(1H, d, 3J = 5.4 Hz, H-17), 5.01 (1H, d, 3J = 5.4 Hz, H-16), 5.28 (1H, d, 3J = 6.4 Hz,
H-16), 5.36 (1H, d, 3J = 6.4 Hz, H-17), 6.42-6.44 (1H, m, H-10), 6.95 (1H, dd, 3J =
7.8 Hz, 4J = 1.8 Hz, H-11), 6.99-7.01 (1H, m, H-8), 7.22-7.27 (1H, m, H-9), 7.72-7.74
(3H, m, H-4 and H-6), 7.80-7.82 (2H, m, H-3). 13C{1H} NMR (100 MHz, CDCl3):
δC(ppm) = 18.47 (C-19), 21.68 (C-13), 22.66 (C-13), 30.41 (C-14), 80.25 (C-16), 83.08
(C-17), 83.25 (C-17), 86.59 (C-16), 98.31 (C-15), 101.74 (C-18), 114.50 (C-10), 117.95
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(C-7), 122.91 (C-8), 123.85 (q, 1JC−F = 270.1 Hz, C-1), 124.38 (C-4), 126.14 (q, 3JC−F
= 2.9 Hz, C-3), 129.12 (q, 2JC−F = 30.0 Hz, C-2), 135.46 (C-11), 136.08 (C-9), 160.83
(C-5), 164.6 (C-6), 165.66 (C-12). 19F{1H} NMR (376 MHz, CDCl3): δF (ppm)
= -62.21 (s). IR (ATR): νmax/cm
−1 = 1615 (C=N). ESI-MS (HR) m/z 238.1773
(100%, [M+H+Na]2+ requires 238.2999). Analysis Calc. for C24H23ClF3NORu:
C, 53.88; H, 4.33; N, 2.62. Found: C, 53.55; H, 4.14; N, 2.10.
6.3.1.5 Rhodium trifluoro complex (2.9)
2.2 (0.0866 g, 0.327 mmol) and triethylamine (0.1 mL, 0.717 mmol) were reacted with
[RhCl(µ-Cl)(Cp*)]2 (0.101 g, 0.167 mmol). Complex 2.9 was isolated as an orange
powder. Yield: 0.132 g (75.0 %). Melting Point: 241°C to dec. with melting. 1H
NMR (400 MHz, CDCl3): δH(ppm) = 1.35 (15H, s, H-13), 6.43-6.47 (1H, m,
H-10), 7.01-7.07 (2H, m, H-8 and H-11), 7.24-7.28 (1H, m, H-9), 7.69 (2H, d, 3J =
8.3 Hz, H-4), 7.94 (1H, s, H-6), 8.01 (2H, d, 3J = 8.1 Hz, H-3). 13C{1H} NMR
(100 MHz, CDCl3): δC(ppm) = 8.42 (C-13), 93.67 (d, JC−Rh = 8.8 Hz, C-14),
114.33 (C-10), 119.21 (C-7), 123.96 (q, 1JC−F = 272.2 Hz, C-1), 124.35 (C-8), 125.22
(C-4), 125.83 (q, 3JC−F = 3.7 Hz, C-3), 128.90 (q, 2JC−F = 32.5 Hz, C-2), 135.51
(C-11), 135.81 (C-9), 157.15 (C-5), 165.10 (C-6), 166.80 (C-12). 19F{1H} NMR (376
MHz, CDCl3): δF (ppm) = -62.15 (s). IR (ATR): νmax/cm
−1 = 1603 (C=N).
ESI-MS (HR) m/z 502.0861 (100%, [M-Cl]+ requires 502.0865). Analysis Calc.
for C24H24ClF3NORh: C, 53.60; H, 4.50; N, 2.60. Found: C, 53.03; H, 4.31; N,
2.08.
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6.3.1.6 Iridium trifluoro complex (2.10)
2.2 (0.0685 g, 0.258 mmol) and triethylamine (0.1 mL, 0.717 mmol) were reacted with
[IrCl(µ-Cl)(Cp*)]2 (0.0998 g, 0.125 mmol). Complex 2.10 was isolated as an orange
powder. Yield: 0.108 g (69.0 %). Melting Point: 243°C to dec. with melting. 1H
NMR (400 MHz, CDCl3): δH (ppm) = 1.33 (15H, s, H-13), 6.46 (1H, t,
3J = 7.2
Hz, H-10), 6.97 (1H, d, 3J = 8.6 Hz, H-8), 7.11 (1H, d, 3J = 7.6 Hz, H-11), 7.37 (1H,
t, 3J = 7.2 Hz, H-9), 7.67 (2H, d, 3J = 8.1 Hz, H-4), 7.85 (2H, d, 3J = 8.1 Hz, H-3),
8.01 (1H, s, H-6). 13C{1H} NMR (100 MHz, CDCl3): δC(ppm) = 8.43 (C-13),
85.81 (C-14), 115.21 (C-10), 120.09 (C-7), 123.53 (C-8), 123.80 (q, 1JC−F = 272.6 Hz,
C-1), 125.45 (C-4), 125.57 (q, 3JC−F = 3.7 Hz, C-3), 129.77 (q, 2JC−F = 32.5 Hz,
C-2), 134.65 (C-11), 135.77 (C-9), 159.12 (C-5), 161.41 (C-6), 164.34 (C-12). 19F{1H}
NMR (376 MHz, CDCl3): δF (ppm) = -62.17 (s). IR (ATR): νmax/cm
−1 = 1615
(C=N). ESI-MS (HR) m/z 592.1528 (80%, [M-Cl]+ requires 592.1439). Analysis
Calc. for C24H24ClF3IrNO: C, 45.97; H, 3.86; N, 2.23. Found: C, 45.63; H, 3.87;
N, 1.75.
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6.3.1.7 Ruthenium silane complex (2.11)
2.3 (0.0876 g, 0.372 mmol) and triethylamine (0.1 mL, 0.717 mmol) were reacted with
[RuCl(µ-Cl)(p-cymene)]2 (0.137 g, 0.224 mmol). Complex 2.11 was isolated as a dark
brown crystalline powder. Yield: 0.0884 g (46.2%). Melting Point: 146°C to dec.
with melting. 1H NMR (400 MHz, CDCl3): δH (ppm) = 0.05 (9H, s, H-1),
0.44-0.54 (1H, m, H-2), 0.60-0.70 (1H, m, H-2), 1.15 (3H, d, 3J = 6.9 Hz, H-12), 1.25
(3H, d, 3J = 7.1 Hz, H-12), 1.84-1.96 (1H, m, H-3), 2.00-2.14 (1H, m, H-3), 2.22 (3H,
s, H-18), 2.79 (1H, sept, 3J = 7.0 Hz, H-13), 3.94-4.04 (1H, m, H-4), 4.20-4.29 (1H,
m, H-4), 5.02 (1H, d, 3J = 8.6 Hz, H-16), 5.39 (3H, m, H-15 and H-16), 6.38-6.42
(1H, m, H-9), 6.90-6.97 (2H, m, H-7 and H-10), 7.13-7.19 (1H, m, H-8), 7.67 (1H, s,
H-5). 13C{1H} NMR (100 MHz, CDCl3) : δC(ppm) = -1.70 (C-1), 14.13 (C-2),
18.49 (C-18), 21.61 (C-12), 22.70 (C-12), 25.74 (C-3), 30.46 (C-13), 72.69 (C-4), 80.11
(C-16), 82.07 (C-16), 83.25 (C-15), 85.86 (C-15), 97.24 (C-17), 101.57 (C-14), 113.97
(C-9), 119.21 (C-6), 122.22 (C-7), 134.33 (C-8), 134.46 (C-10), 163.34 (C-5), 164.92
(C-11). IR (ATR): νmax/cm
−1 = 1618 (C=N). ESI-MS (HR) m/z 470.1460 (100%,
[M-Cl]+ requires 470.1459). Analysis Calc. for C23H34ClNORuSi·0 · 6 H2O: C,
53.42; H, 6.89; N, 2.71. Found: C, 53.17; H, 6.81; N, 2.47.
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6.3.1.8 Rhodium silane complex (2.12)
2.3 (0.0997 g, 0.423 mmol) and triethylamine (0.1 mL, 0.717 mmol) were reacted with
[RhCl(µ-Cl)(Cp*)]2 (0.126 g, 0.204 mmol). Complex (2.12) was isolated as a red
powder. Yield: 0.101 g (48.8 %). Melting Point: 166°C to dec. with melting. 1H
NMR (400 MHz, CDCl3): δH (ppm) = -0.01 (9H, s, H-1), 0.48-0.52 (2H, m, H-2),
1.53 (15H, s, H-12), 1.68-1.71 (1H, m, H-3), 2.15-2.25 (1H, m, H-3), 3.80-4.03 (2H,
m, H-4), 6.41-6.45 (1H, m, H-9), 6.92 (1H, d, 3J = 8.4 Hz, H-7), 7.01 (1H, dd, 3J
= 7.7 Hz, 4J = 1.7 Hz, H-10), 7.13-1.17 (1H, m , H-8), 7.78 (1H, s, H-5). 13C{1H}
NMR (100 MHz, CDCl3) : δC(ppm) = -1.72 (C-1), 8.61 (C-12), 14.02 (C-2),
25.28 (C-3), 66.97 (C-4), 92.65 (d, 1JC−Rh = 8.1 Hz, C-13), 114.05 (C-9), 121.92 (C-6),
123.70 (C-7), 133.71 (C-8), 133.90 (C-10), 162.31 (C-5), 166.60 (C-11). IR (ATR):
νmax/cm
−1 = 1621 (C=N). ESI-MS (HR) m/z 472.1551 (100%, [M-Cl]+ requires
472.1543). Analysis Calc. for C23H35ClNORhSi·0.2 Et2O: C, 54.68; H, 7.13; N,
2.68. Found: C, 55.32; H, 6.86; N, 2.39.
6.3.1.9 Iridium silane complex (2.13)
2.3 (0.0337 g, 0.143 mmol) and triethylamine (0.1 mL, 0.717 mmol) was reacted with
[IrCl(µ-Cl)(Cp*)]2 (0.0697 g, 0.0875 mmol). Complex 2.13 was isolated as a fine yellow
powder. Yield: 0.0478 g (56.0 %). Melting Point: 158°C to dec. with melting. 1H
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NMR (300 MHz, CDCl3): δH(ppm) = 0.03 (9H, s, H-1), 0.51 (2H, br m, H-2),
1.56 (15H, s, H-12), 1.70-1.93 (1H, br m, H-3), 1.94-2.17 (1H, br m, H-3), 3.75-4.20
(2H, br m, H-4), 6.40-6.44 (1H, m, H-9), 6.87-6.90 (1H, m, H-7), 7.04 (1H, dd, 3J = 7.7
Hz, 4J = 1.8 Hz, H-10), 7.21-7.25 (1H, m, H-8), 7.75 (1H, s, H-5). 13C{1H} NMR
(100 MHz, CDCl3): δC(ppm) = -1.70 (C-1), 8.83 (C-12), 14.03 (C-2), 25.45 (C-
3), 69.86 (C-4), 84.64 (C-13), 114.79 (C-9), 121.88 (C-6), 122.71 (C-7), 133.15 (C-8),
134.00 (C-10), 159.72 (C-5), 165.19 (C-11). IR (ATR): νmax/cm
−1 = 1619 (C=N).
ESI-MS (HR) m/z 562.2133 (100%, [M-Cl]+) requires 562.2117. Analysis Calc.
for C23H35ClIrNOSi· 0.2 Et2O: C, 46.70; H, 6.09; N, 2.29. Found: C, 47.11; H,
5.86; N, 1.79.
6.3.1.10 Ruthenium ferrocenyl complex5 (2.14)
2.4 (0.280 g, 0.843 mmol) and triethylamine (0.120 mL, 0.840 mmol) were reacted with
[RuCl(µ-Cl)(p-cymene)]2 (0.254 g, 0.415 mmol). Complex 2.14 was isolated as a dark
red powder. Yield: 0.380 g (75.1 %). Melting Point: 197°C to dec. with melting.
1H NMR (400 MHz, CDCl3): δH(ppm) = 1.17 (3H, d,
3J = 6.8 Hz, H-13), 1.22
(3H, d, 3J = 7.0 Hz, H-13), 2.23 (3H, s, H-19), 2.83 (1H, sept, 3J = 7.0 Hz, H-14), 4.29
(5H, s, H-1), 4.50 – 4.54 (2H, m, H-2 and H-3), 4.64 – 4.66 (1H, m, H-2), 4.77 – 4.78
(1H, m, H-3), 5.16 (1H, d, 3J = 5.7 Hz, H-17), 5.43 (2H, br s, H-16), 5.48 (1H, d, 3J =
5.8 Hz, H-17), 6.43 – 6.47 (1H, m, H-10), 6.97 (1H, dd, 3J = 7.7 Hz, 4J = 1.8 Hz, H-8),
7.01 (1H, d, 3J = 8.4 Hz, H-11), 7.20 – 7.21 (1H, m, H-9), 7.80 (1H, s, H-6), 8.74 (1H,
s, H-5). 13C{1H} NMR (100 MHz, CDCl3): δC(ppm) = 18.84 (C-19), 21.98
(C-13), 22.83 (C-13), 30.83 (C-14), 67.94 (C-3), 69.85 (C-1), 69.96 (C-2), 71.48 (C-2),
71.71 (C-3), 76.64 (C-4), 81.33 (C-17), 82.20 (C-17), 83.54 (C-16), 84.19 (C-16), 98.00
(C-18), 103.03 (C-15), 114.68 (C-9), 117.92 (C-7), 122.98 (C-8), 134.15 (C-11), 134.64
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(C-10), 155.41 (C-6), 163.03 (C-5), 166.13 (C-12). IR (ATR): νmax/cm
−1 = 1600
(C=N). EI-MS m/z 602.04 ([M]+, 10%). Analysis Calc. for C28H29ClFeN2ORu:
C, 55.87; H, 4.86; N, 4.65. Found: C, 55.90; H, 5.00; N, 4.37.
6.3.1.11 Rhodium ferrocenyl complex5 (2.15)
2.4 (0.221 g, 0.665 mmol) and triethylamine (0.1 mL, 0.717 mmol) was reacted with
[RhCl(µ-Cl)(Cp*)]2 (0.201 g, 0.325 mmol). Complex 2.15 was isolated as a dark red
powder. Yield: 0.110 g (27.9 %). Melting Point: 152°C to dec. with melting. 1H
NMR (400 MHz, CDCl3): δH (ppm) = 1.54 (15H, s, H-13), 4.31 (5H, s, H-1), 4.47
– 4.49 (1H, m, H-2), 4.51 – 4.52 (1H, m, H-3), 4.56 – 4.58 (1H, m, H-2), 4.83 – 4.85 (1H,
m, H-3), 6.49 – 6.53 (1H, m, H-10), 7.01 (1H, d, 3J = 8.4 Hz, H-8), 7.11 (1H, dd, 3J
= 7.8 Hz, 4J = 1.8 Hz, H-11), 7.20 – 7.25 (1H, m, H-9), 8.31 (1H, s, H-6), 9.24 (1H, s,
H-5). 13C{1H} NMR (100 MHz, CDCl3): δC(ppm) = 9.07 (C-13), 66.44 (C-3),
70.06 (C-1), 71.29 (C-2), 71.34 (C-2), 71.79 (C-3), 76.55 (C-4), 93.59 (d, 1JC−Rh =
8.1 Hz, C-14), 115.04 (C-9), 120.04 (C-7), 124.13 (C-11), 134.43 (C-8), 134.69 (C-10),
160.35 (C-6), 165.71 (C-5), 167.73 (C-12). IR (ATR): νmax/cm
−1 = 1611 (C=N).
EI-MS m/z 604.04 ([M]+, 10%). Analysis Calc. for C28H30ClFeN2ORh: C,
55.61; H, 5.00; N, 4.63. Found: C, 55.68; H, 5.53; N, 4.47.
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6.3.1.12 Iridium ferrocenyl complex5 (2.16)
2.4 (0.172 g, 0.519 mmol) and triethylamine (0.1 mL, 0.717 mmol) was reacted with
[IrCl(µ-Cl)(Cp*)]2 (0.200 g, 0.251 mmol). Complex 2.16 was isolated as an orange
powder. Yield: 0.102 g (29.1 %). Melting Point: 200°C to dec. with melting. 1H
NMR (400 MHz, CDCl3): δH (ppm) = 1.54 (15H, s, H-13), 4.31 (5H, s, H-1), 4.47
– 4.49 (1H, m, H-2), 4.51 – 4.52 (1H, m, H-3), 4.56 – 4.58 (1H, m, H-2), 4.83 – 4.85
(1H, m, H-3), 6.49 – 6.53 (1H, m, H-10), 7.01 (1H, d, 3J = 8.4 Hz, H-8), 7.11 (1H, dd,
3J = 7.8 Hz, 4J = 1.8 Hz, H-11), 7.20 – 7.25 (1H, m, H-9), 8.31 (1H, s, H-6), 9.24 (1H,
s, H-5). 13C{1H} NMR (100 MHz, CDCl3): δC(ppm) = 9.27 (C-13), 66.70 (C-3),
70.07 (C-1), 71.34 (C-2), 71.40 (C-2), 71.86 (C-3), 76.12 (C-4), 85.55 (C-14), 115.88
(C-9), 120.58 (C-7), 123.08 (C-11), 133.73 (C-8), 134.65 (C-10), 157.42 (C-6), 166.45
(C-12), 166.90 (C-5). IR (ATR): νmax/cm
−1 = 1594 (C=N), 1618 (C=N). EI-MS
m/z 694.15 ([M]+, 20%). Analysis Calc. for C28H30ClFeIrN2O: C, 48.45; H, 4.36;
N, 4.04. Found: C, 48.61; H, 4.41; N, 3.88.
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6.4 Alkylated benzyl PTA scaffold (3.1) and mono-
cationic complexes (3.2-3.4)
6.4.1 Alkylated Benzyl PTA Scaffold7 (3.1)
Under an inert atmosphere (Ar(g)), a solution of 1,3,5-triaza-7-phosphaadamantane
(0.206 g,1.30 mmol) and benzyl chloride (0.220 g, 1.74 mmol) in THF (15 mL) was
refluxed for 16 hours. A white precipitate was observed after this time, filtered and
washed with cold THF (2 x 10 mL). The sample was then dried in vacuo. Compound
3.1 was isolated as a white solid. Yield: 0.367 g (98.8 %). Melting Point: 187-190
°C. S293: (g/L ± SE, H2O) = 22.0 ± 4.4. 1H NMR (400 MHz, CD3OD-d4):
δH(ppm) = 3.82 - 3.99 (4H, m, H-9), 4.18 (2H, s, H-5), 4.30 (2H, d,
2J = 4.0 Hz,
H-8), 4.49 - 4.52 (1H, m, H-7), 4.61 - 4.65 (1H, m, H-7), AB spin system with A at
4.96 ppm and B at 5.10 ppm (4H, JAB = 8.00 Hz, H-6), 7.54 - 7.57 (5H, m, H-1,
H-2 and H-3). 13C{1H} (100 MHz, CD3OD-d4): δC(ppm) = 47.62 (d, 1JC−P
= 21.13 Hz, C-9), 54.26 (d, 1JC−P = 34.22 Hz, C-8), 67.29 (C-5), 71.49 (C-7), 81.14
(C-6), 126.87 (C-4), 130.59 (C-2), 131.98 (C-1), 134.24 (C-3). 31P{1H} (162 MHz,
CD3OD-d4): δP (ppm) = -81.43 (s). ESI-MS (HR) m/z 248.1318 (100 %, [M-
Cl]+ requires 248.1317). Analysis for C13H19ClN3P·0.5H2O: C, 53.34; H, 6.89; N,
14.35. Found: C, 53.28; H, 6.93; N, 15.60.
6.4.2 General Synthesis
Synthesis of 3.2-3.4
A suspension of 3.1 and [RuCl(µ-Cl)(p-cymene)]2, [RhCl(µ-Cl)(Cp*)]2 or [IrCl(µ-
Cl)(Cp*)]2 in dichloromethane was left to stir for 4 hours under an inert atmosphere
(Ar). The resulting suspension was filtered by gravity to remove excess 3.1, the filtrate
collected and the solvent removed. The crystalline residue was washed with a mixture
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of dichloromethane:diethyl ether (5:95 v/v %) and the isolated complex was dried in
vacuo.
6.4.2.1 Ruthenium dichlorido PTA complex8 (3.2)
The alkylated benzyl PTA scaffold 3.1 (0.0474 g, 0.167 mmol) was reacted with
[RuCl(µ-Cl)(p-cymene)]2 (0.0523 g, 0.0854 mmol). Complex 3.2 was isolated as red
crystalline flakes. Yield: 0.0691 g (68.6 %). Melting Point: 190°C– dec. with melt-
ing. S293: (g/L ± SE, H2O) = 12.2 ± 1.2. 1H NMR (400 MHz, CDCl3):
δH(ppm) = 1.22 (6H, d,
3J = 6.8 Hz, H-10), 2.09 (3H, s, H-16), 2.79 (1H, sept, 3J =
6.8 Hz, H-11), 4.18-4.21 (2H, m, H-9), 4.38 (2H, s, H-5), 4.44-4.47 (2H, m, H-9), 4.62
(2H, br s, H-8), 5.02-5.04 (2H, m, H-6), 5.27-5.31 (2H, m, H-7), 5.61-5.63 (2H, m, H-6),
5.95-6.05 (4H, m, H-13 and H-14), 7.49-7.61 (5H, m, H-1, H-2 and H-3). 13C{1H}
NMR (100 MHz, CDCl3): δC(ppm) = 18.45 (C-16), 21.93 (C-10), 30.76 (C-11),
48.21 (d, 1JC−P = 20.5 Hz, C-9), 54.92 (d, 3JC−P = 10.1 Hz, C-7), 65.99 (C-8), 70.59
(d, 3JC−P = 3.2 Hz, C-5), 79.54 (C-6), 86.16 (d, 2JC−P = 5.9 Hz, C-14), 89.82 (d,
2JC−P = 4.4 Hz, C-13), 97.10 (C-15), 107.94 (C-12), 128.99 (C-4), 129.70 (C-2), 131.35
(C-1), 132.83 (C-3). 31P{1H} NMR (162 MHz, CDCl3): δP (ppm) = -20.07 (s).
ESI-MS (HR) m/z 554.0833 (100 %, [M-Cl]+ requires 554.0832). Analysis Calc.
C23H33Cl3N3PRu · 2 H2O: C, 44.13; H, 5.96; N, 6.71. Found: C, 43.89; H, 5.77; N,
6.70.
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6.4.2.2 Rhodium dichlorido PTA complex8 (3.3)
The alkylated benzyl PTA scaffold 3.1 (0.0707 g, 0.249 mmol) was reacted with
[RhCl(µ-Cl)(Cp*)]2 (0.0702 g, 0.114 mmol). Complex 3.3 was isolated as red crys-
talline flakes. Yield: 0.0781 g (58.0 %). Melting Point: 124°C– dec. with melting.
S293: (g/L ± SE, H2O) =11.5 ± 5.7. 1H NMR (400 MHz, CDCl3): δH(ppm) =
1.82 (15H, d, 4JH−P = 4.0 Hz, H-10), 4.26-4.28 (4H, m, H-9), 4.42 (1H, d, 2J = 13.7 Hz,
H-7), 4.57 (1H, d, 2J = 14.1 Hz, H-7), 4.89-4.92 (2H, m, H-5), 5.03-5.05 (2H, d, 1JH−P
= 2.6 Hz, H-8), 5.41-5.43 (4H, br m, H-6), 7.43-7.50 (3H, m, H-1 and H-2), 7.62 (2H,
m, H-3). 13C{1H} NMR (100 MHz, CDCl3): δC(ppm) = 9.86 (C-10), 47.22 (d,
1JC−P = 16.1 Hz, C-9), 52.04 (d, 1JC−P = 9.5 Hz, C-8), 65.13 (C-5), 70.22 (C-7), 79.05
(C-6), 100.63 (d, 1JC−Rh = 3.7 Hz, C-11), 125.03 (C-4), 129.51 (C-2), 131.05 (C-1),
133.03 (C-3). 31P{1H} NMR (162 MHz, CDCl3): δP (ppm) = -24.16 (d, 1JP−Rh
= 150.7 Hz). ESI-MS (HR) m/z 556.0906 (100 %, [M-Cl]+ requires 556.0922).
Analysis Cal. for C23H34Cl3N3PRh · 2 H2O: C, 43.93; H, 6.09; N, 6.68. Found:
C, 43.60; H, 6.05; N, 6.36.
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6.4.2.3 Iridium dichlorido PTA complex8 (3.4)
The alkylated benzyl PTA scaffold 3.1 (0.0604 g, 0.213 mmol) was reacted with [IrCl(µ-
Cl)(Cp*)]2 (0.0805 g, 0.101 mmol). Complex 3.4 was isolated as orange crystalline
flakes. Yield: 0.0681 g (49.4 %). Melting Point: 176°C– dec. with melting. S293:
(g/L ± SE, H2O) = 13.7 ± 3.4. 1H NMR (400 MHz, CDCl3): δH(ppm) =
1.87 (15H, d, 4JH−P = 2.0 Hz, H-10), 4.23 (4H, m, H-9), 4.41 (1H, d, 2J = 13.4 Hz,
H-7), 4.68 (1H, d, 2J = 13.4 Hz, H-7), 4.90-5.00 (4H, m , H-5 and H-8), 5.37 (2H, d,
2J = 11.2 Hz, H-6), 5.54 (2H, d, 2J = 11.5 Hz, H-6), 7.43-7.53 (3H, m, H-1 and H-2),
7.63 (2H, d, 3J = 7.1 Hz, H-3). 13C{1H} NMR (100 MHz, CDCl3): δC(ppm) =
9.48 (C-10), 45.77 (d, 1JC−P = 23.5 Hz, C-9), 50.12 (d, 1JC−P = 19.1 Hz, C-8), 64.90
(C-5), 70.29 (d, 3JC−P = 5.9 Hz, C-7), 79.17 (C-6), 94.13 (d, 2JC−P = 2.2 Hz, C-11),
125.01 (C-4), 129.47 (C-2), 130.99 (C-1), 132.99 (C-3). 31P{1H} NMR (162 MHz,
CDCl3): δP (ppm) = -51.26 (s). ESI-MS (HR) m/z 305.5901 (100%, [M-2Cl]
2+
requires 305.5904). Analysis Calc. for C23H34Cl3IrN3P · (C2H5)2O: C, 42.88; H,
5.87; N, 5.56. Found: C, 42.88; N, 6.02; N, 5.87.
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6.5 (N,O)-Salicylaldimine metal PTA dicationic com-
plexes (3.5-3.16)
6.5.1 General Synthesis
(i) Synthesis of 3.5-3.7
A suspension of the alkylated benzyl PTA scaffold 3.1 and 2.5, 2.6 or 2.7 in dichloro-
methane was left to stir for 24 hours under an inert atmosphere (Ar) at ambient
temperature. The resulting suspension was filtered by gravity to remove excess 3.1,
the filtrate collected and the solvent removed. The resulting solid was washed with a
mixture of dichloromethane:diethyl ether (5:95 v/v %) and the resulting amorphous
powder dried in vacuo.
(ii) Synthesis of 3.8-3.10, 3.14 and 3.15
Under an inert atmosphere (Ar), silver hexafluorophosphate and 2.8, 2.9, 2.10, 2.15
or 2.16 were stirred in acetone at -40 °C. The resulting solution was warmed to room
temperature and stirred for an additional 60 minutes. The solution was then cooled to
-40 °C and 3.1 added. The mixture was then warmed to room temperature. The sus-
pension was stirred for an additional 30 minutes, the mixture filtered through Celite®,
the filtrate collected and the solvent removed in vacuo. The residue was dried in vacuo
to yield the proposed complex as an amorphous powder.
(iii) Synthesis of 3.11-3.13
A solution of 3.1 and 2.11, 2.13 or 2.14 in dry ethanol (10 mL) was left to stir for
24 hours under an inert atmosphere (Ar). The solvent was removed to yield a red or
orange residue. This residue was dissolved in a minimal amount of dichloromethane,
filtered by gravity to remove excess 3.1 and the product precipitated using n-pentane.
The resulting powder was filtered by vacuum filtration and dried in vacuo.
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6.5.1.1 Ruthenium propylsalicylaldimine PTA complex (3.5)
3.1 (0.0335 g, 0.118 mmol) was reacted with 2.5 (0.0496 g, 0.115 mmol). Complex 3.5
was isolated as a green powder. Yield: 0.0653 g (76.3 %). Melting Point: 164°C to
dec. with melting. 1H NMR (400 MHz, CD3OD-d4): δH(ppm) = 1.11 (6H, m,
H-1 and H-20), 1.28 (3H, d, 3J = 7.0 Hz, H-20), 1.95-2.04 (2H, m, H-2), 2.17 (3H, s,
H-26), 2.58 (1H, sept, 3J = 7.0 Hz, H-21), 3.59-3.67 (1H, m, H-3), 3.89 (1H, m, H-19),
3.96-4.07 (1H, m, H-3), 4.21 (1H, m, H-19), 4.36-4.67 (7H, m, H-19 and H-18 and H-15
and H-17), 4.82-4.86 (1H, m, H-17), 5.04-5.07 (1H, m, H-16), 5.18-5.29 (3H, m, H-16),
5.71 (1H, d, 3J = 5.9 Hz, H-23), 5.87 (1H, d, 3J = 5.9 Hz, H-24), 6.39 (1H, d, 3J = 5.9
Hz, H-24), 6.55-6.58 (1H, m, H-23), 6.63-6.67 (2H, m, H-6 and H-8), 7.22-7.26 (2H, m,
H-9 and H-11), 7.37-7.45 (4H, m, H-12 and H-13), 7.51-7.60 (1H, m, H-7), 8.11 (1H,
d, 4J = 2.0 Hz, H-4). 13C{1H} NMR (100 MHz, CD3OD-d4): δC(ppm) = 11.53
(C-1), 18.86 (C-26), 21.82 (C-20), 22.59 (C-20), 26.19 (C-2), 32.29 (C-21), 48.62 (C-
19), 51.77 (d, 1JC−P = 11.7 Hz, C-18), 66.55 (C-15), 70.75 (d, 3JC−P = 5.9 Hz, C-17),
73.76 (C-3), 80.84 (d, 3JC−P = 2.9 Hz, C-16), 86.86 (C-23), 89.34 (C-25), 89.43 (C-24),
90.82 (C-23), 93.51 (C-24), 101.62 (C-22), 117.58 (C-8), 122.55 (C-5), 123.48 (C-6),
130.02 (C-14), 130.71 (C-12), 132.07 (C-11), 134.07 (C-13), 136.74 (C-9), 136.99 (C-7),
164.25 (C-10), 169.13 (C-4). 31P{1H} NMR (162 MHz, CD3OD-d4): δP (ppm)
= -13.77 (s). IR (ATR): νmax/cm
−1 = 1598 (C=N). ESI-MS (HR) m/z 681.2059
(15%, [M-Cl]+ requires 681.2058). Analysis Calc. C33H45Cl2N4OPRu · 2 H2O:
C, 52.66; H, 6.56; N, 7.44. Found: C, 52.15; H, 6.41; N, 7.86.
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6.5.1.2 Rhodium propylsalicylaldimine PTA complex (3.6)
3.1 (0.0205 g, 0.0772 mmol) was reacted with 2.6 (0.0296 g, 0.0679 mmol). Compound
3.6 was isolated as a red powder. Yield: 0.0257 g (52.6 %). Melting Point: 87°C to
dec. with melting. S293: (g/L ± SE, H2O) = 19.3 ± 3.1. 1H NMR (400 MHz,
CD3OD-d4): δH (ppm) = 1.12 (3H, t,
3J = 7.3 Hz, H-1), 1.72 (15H, d, 4JH−P =
3.9 Hz, H-20), 1.87-1.96 (1H, m, H-2), 1.98-2.09 (1H, m, H-2), 3.67-3.72 (1H, m, H-3),
3.85-3.93 (1H, m, H-3), 4.03-4.06 (1H, m, H-19), 4.15-4.19 (1H, m, H-19), 4.30-4.35
(2H, m, H-19), 4.44-4.59 (5H, m, H-15 and H-17 and H-18), 4.81-4.85 (1H, m, H-17),
5.06-5.09 (1H, m, H-16), 5.18-5.26 (3H, m, H-16), 6.69-6.74 (2H, m, H-6 and H-8), 7.28-
7.35 (2H, m, H-12), 7.40 (4H, m, H-9 and H-11 and H-13), 7.48-7.52 (1H, m, H-7), 8.26
(1H, s, H-4). 13C{1H} NMR (100 MHz, CD3OD-d4): δC(ppm) = 9.68 (C-20),
11.54 (C-1), 25.39 (C-2), 46.85 (d, 1JC−P = 10.1 Hz, C-19), 48.08 (d, 1JC−P = 14.1
Hz, C-19), 50.64 (d, 1JC−P = 11.1 Hz, C-18), 66.52 (C-15), 69.10 (C-17), 70.79 (C-3),
80.97 (d, 3JC−P = 37.2 Hz, C-16), 102.57 (d, 1JC−Rh = 5.1 Hz, C-21), 117.92 (C-8),
118.93 (C-5), 125.04 (C-6), 126.12 (C-14), 130.69 (C-12), 132.18 (C-11), 134.05 (C-
13), 137.00 (C-7 and C-9), 166.98 (C-10), 168.18 (C-4). 31P{1H} NMR (162 MHz,
CD3OD-d4): δP (ppm) = -22.67 (d,
1JP−Rh = 152.0 Hz). IR (ATR): νmax/cm−1 =
1619 (C=N). ESI-MS (HR) m/z 683.2157 (10%, [M-Cl]+ requires 683.2147).
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6.5.1.3 Iridium propylsalicylaldimine PTA complex (3.7)
3.1 (0.0281 g, 0.0990 mmol) was reacted with 2.7 (0.0506 g, 0.0964 mmol). Complex
3.7 was isolated as a yellow powder. Yield: 0.0653 g (83.8%). Melting Point: 137°C
to dec. with melting. S293: (g/L, H2O) = 33.4 ± 3.2. 1H NMR (400 MHz,
CD3OD-d4): δH (ppm) = 1.09 (3H, t,
3J = 7.3 Hz, H-1), 1.75-1.76 (15H, m, H-20),
1.93-1.99 (1H, m, H-2), 2.05-2.11 (1H, m, H-2), 3.72-3.80 (1H, m, H-3), 3.94-4.02 (1H,
m, H-3), 4.08-4.18 (2H, m, H-19), 4.26-4.39 (2H, m, H-19), 4.43-4.48 (4H, m, H-15
and H-18), 4.60-4.63 (1H, m, H-17), 4.80-4.82 (1H, m, H-17), 5.06-5.09 (1H, m, H-16),
5.21-5.28 (3H, m, H-16), 6.70-6.76 (2H, m, H-6 and H-8), 7.37-7.43 (6H, m, H-9 and
H-11 and H-12 and H-13), 7.50-7.53 (1H, m, H-7), 8.14 (1H, s, H-4). 13C{1H} NMR
(100 MHz, CD3OD-d4): δC(ppm) = 9.60 (C-20), 11.29 (C-1), 25.41 (C-2), 46.00
(d, 1JC−P = 20.1 Hz, C-19), 47.03 (d, 1JC−P = 17.6 Hz, C-18), 66.41 (C-15), 70.82 (C-
17), 72.24 (C-3), 80.97 (C-16), 96.66 (C-21), 118.82 (C-8), 123.37 (C-5), 123.58 (C-6),
126.16 (C-14), 130.73 (C-12), 132.19 (C-11), 134.06 (C-13), 136.41 (C-9), 137.08 (C-7),
163.40 (C-10), 165.69 (C-4). 31P{1H} NMR (162 MHz, CD3OD-d4): δP (ppm)
= -42.69 (s). IR (ATR): νmax/cm
−1 = 1625 (C=N). ESI-MS (HR) m/z 773.2709
(55%, [M-Cl]+ requires 773.2722). Analysis Calc. C33H46Cl2IrN4OP · 7 H2O: C,
42.39; H, 6.47; N, 5.99. Found: C, 42.81; H, 5.55; N, 5.78.
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6.5.1.4 Ruthenium trifluorosalicylaldimine PTA complex (3.8)
Silver hexafluorophosphate (0.0430 g, 0.169 mmol), 2.8 (0.0412 g, 0.0770 mmol) and
3.1 (0.0224 g, 0.0789 mmol) were reacted. Compound 3.8 was isolated as a green
powder. Yield: 0.0351 g (43.9 %). Melting Point: 170°C to dec. with melting. 1H
NMR (400 MHz, CD3OD-d4): δH(ppm) = 1.07 (3H, d,
3J = 6.8 Hz, H-22), 1.16
(3H, d, 3J = 7.1 Hz, H-22), 1.72 (3H, s, H-28), 2.25 (1H, sept, 3J = 6.9 Hz, H-23),
3.71-3.75 (1H, m, H-21), 4.07-4.11 (1H, m, H-21), 4.17-4.22 (2H, m, H-21), 4.25-4.31
(2H, m, H-17), 4.42-4.50 (2H, m, H-20), 4.53-4.57(1H, m, H-19), 4.71-4.73 (1H, m,
H-19), 4.82-4.85 (1H, m, H-18), 5.07-5.24 (3H, m, H-18), 5.45 (1H, d, 3J = 5.4 Hz,
H-26), 6.21 (1H, d, 3J = 6.1 Hz, H-25), 6.32-6.35 (1H, m, H-25), 6.61-6.67 (2H, m,
H-26 and H-10), 7.24-7.29 (2H, m, H-8 and H-11), 7.37-7.39 (2H, m, H-14), 7.45-7.52
(5H, m, H-3, H-13 and H-15), 7.56-7.60 (1H, m, H-9), 7.90-7.92 (2H, m, H-4), 8.14 (1H,
d, 4J = 2.2 Hz, H-6). 31P{1H} NMR (162 MHz, CD3OD-d4): δP (ppm) = -144.3
(2P, sept, 1JP−F = 708.8 Hz,PF6), -16.77 (1P, s, P(CH2N)3). IR (ATR): νmax/cm
−1
= 1600 (C=N). ESI-MS (HR) m/z 893.1887 (40%, [M-PF6]
+ requires 893.1734).
Analysis Calc. C37H42F15N4OP3Ru: C, 42.82; H, 4.06; N, 5.40. Found: C, 42.29;
H, 3.87; N, 5.20.
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6.5.1.5 Rhodium trifluorosalicylaldimine PTA complex (3.9)
Silver hexafluorophosphate (0.0330 g, 0.130 mmol), 2.9 (0.0321 g, 0.0632 mmol) and
3.1 (0.0191 g, 0.0673 mmol) were reacted. Compound 3.9 was isolated as a red powder.
Yield: 0.0114 g (17.3 %). Melting Point: 180°C to dec. with melting. 1H NMR
(400 MHz, CD3OD-d4): δH(ppm) = 1.34-1.46 (15H, m, H-22), 3.99-4.07 (2H,
m, H-21), 4.17-4.20 (1H, m, H-21), 4.27-4.28 (2H, m, H-17), 4.41-4.45 (1H, m, H-
21), 4.53-4.57 (2H, m, H-20), 4.65-4.71 (1H, m, H-19), 4.82-4.91 (2H, m, H-18 and
H-19), 4.99-5.02 (1H, m, H-18), 5.15-5.21 (2H, m, H-18), 6.73-6.76 (1H, m, H-10),
6.83-6.85 (1H, m, H-8), 7.32-7.34 (2H, m, H-14), 7.43-7.53 (7H, m, H-3, H-9, H-11, H-
13 and H-15), 7.94-7.96 (2H, m, H-4), 8.50 (1H, s, H-6). 31P{1H} NMR (162 MHz,
CD3OD-d4): δP (ppm) = -144.42 (2P, sept,
1JP−F = 708.8 Hz, PF6), -26.52 (1P, d,
1JP−Rh = 148.7 Hz, P(CH2N)3). IR (ATR): νmax/cm−1 = 1599 (C=N). ESI-MS
(HR) m/z 1040.1489 (20%, [M]+ requires 1040.1465), 502.0871 (100%, [M-2PF6-
C13H19N3P]
+ requires 502.0865). Analysis Calc. C37H43F15N4OP3Rh · 4 H2O:
C, 39.94; H, 4.62; N, 5.04. Found: C, 39.76; H, 4.45; N, 4.73.
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6.5.1.6 Iridium trifluorosalicylaldimine PTA complex (3.10)
Silver hexafluorophosphate (0.0420 g, 0.165 mmol), 2.10 (0.0412 g, 0.0657 mmol) and
3.1 (0.0187 g, 0.0659 mmol) were reacted. Compound 3.10 was isolated as a yellow
powder. Yield: 0.0221 g (19.6 %). Melting Point: 164°C– dec. with melting. 1H
NMR (400 MHz, CD3OD-d4): δH(ppm) = 1.49 (15H, d,
4JH−P = 2.7 Hz, H-22),
4.05-4.12 (2H, m, H-21), 4.19-4.30 (2H, m, H-17), 4.39-4.50 (2H, m, H-21), 4.55-4.69
(2H, m, H-20), 4.86-4.95 (2H, m, H-19), 5.00-5.09 (2H, m, H-18), 5.19-5.25 (2H, m,
H-18), 6.74-6.79 (1H, m, H-10), 6.86 (1H, d, 3J = 8.2 Hz, H-8), 7.32-7.35 (2H, m,
H-9 and H-11), 7.44-7.57 (7H, m, H-3, H-13, H-14 and H-15), 7.95 (2H, d, 3J =
8.3 Hz, H-4), 8.47-8.48 (1H, m, H-6). 31P{1H} NMR (162 MHz, CD3OD-d4):
δP (ppm) = -144.41 (2P, sept,
1JP−F = 708.0 Hz, PF6), -44.02 (1P, s, P(CH2N)3). IR
(ATR): νmax/cm
−1 = 1602 (C=N). ESI-MS (HR) m/z 592.1453 (65%, [M-2PF6-
C13H19N3P]
+ requires 592.1453). Analysis Calc. C37H43F15IrN4OP3 ·CH2Cl2:
C, 36.64; H, 3.64; N, 4.50. Found: C, 35.95; H, 3.29; N, 5.01.
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6.5.1.7 Ruthenium silane PTA complex (3.11)
3.1 (0.0178 g, 0.0627 mmol) was reacted with 2.11 (0.0399 g, 0.0790 mmol). Complex
3.11 was isolated as a black powder. Yield: 0.0317 g (64.1 %). Melting Point: 119°C
to dec. with melting. 1H NMR (400 MHz, CD3OD-d4): δH(ppm) = 0.13-0.15
(9H, m, H-1), 0.59-0.75 (2H, m, H-2), 1.13 (3H, d, 3J = 7.0 Hz, H-21), 1.28 (3H, d, 3J
= 7.0 Hz, H-21), 1.98-2.04 (2H, m, H-3), 2.16 (3H, s, H-27), 2.57 (1H, sept, 3J = 7.0
Hz, H-22), 3.52-3.61 (1H, m, H-4), 3.88-3.92 (1H, m, H-20), 4.03-4.10 (1H, m, H-4),
4.18-4.21 (1H, m, H-20), 4.32-4.45 (4H, m, H-16 and H-20), 4.52-4.67 (3H, m, H-18
and H-19), 4.81-4.83 (1H, m, H-18), 5.04-5.07 (1H, m, H-17), 5.17-5.25 (3H, m, H-17),
5.71 (1H, d, 3J = 6.1 Hz, H-24), 5.83 (1H, d, 3J = 5.6 Hz, H-25), 6.35 (1H, d, 3J
= 6.0 Hz, H-25), 6.50-6.53 (1H, m, H-24), 6.65-6.68 (2H, m, H-7 and H-9), 7.25-7.28
(2H, m, H-10 and H-12), 7.34-7.36 (2H, m, H-14), 7.41-7.44 (2H, m, H-13), 7.50-7.54
(1H, m, H-8), 8.08-8.11 (1H, m, H-5). 13C{1H} NMR (100 MHz, CD3OD-d4):
δC(ppm) = -1.48 (C-1), 14.71 (C-2), 18.87 (C-27), 21.89 (C-21), 22.56 (C-21), 27.51
(C-3), 32.27 (C-22), 48.61 (d, 1JC−P = 15.6 Hz, H-20), 50.27 (d, 1JC−P = 15.4 Hz,
H-19), 51.72 (d, 1JC−P = 11.7 Hz, H-20), 66.75 (C-16), 70.87 (d, 3JC−P = 6.6 Hz, H-
18), 75.04 (C-4), 80.95 (C-17), 86.93 (C-24), 89.26 (C-26), 89.36 (C-25), 93.51 (C-24),
101.82 (C-23), 117.65 (C-9), 120.71 (C-14), 122.70 (C-6), 123.53 (C-7), 126.11 (C-10),
130.74 (C-13), 132.10 (C-12), 134.10 (C-10), 136.74 (C-15), 137.02 (C-8), 164.38 (C-
5), 169.13 (C-11). 31P{1H} NMR (162 MHz, CD3OD-d4): δP (ppm) = -13.29
(s). IR (ATR): νmax/cm
−1 = 1601 (C=N). ESI-MS (HR) m/z 735.2667 (75%,
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[M-2Cl+OH]+ requires 735.2792). Analysis Calc. C36H53Cl2N4OPRuSi · 2 H2O:
C, 52.42; H, 6.97; N, 6.79. Found: C, 52.74; H, 6.44; N, 7.31.
6.5.1.8 Iridium silane PTA complex (3.12)
3.1 (0.0201 g, 0.0708 mmol) was reacted with 2.13 (0.0278 g, 0.0465 mmol). Complex
3.12 was isolated as an orange powder. Yield: 0.0173 g (42.2 %). Melting Point: 79
– 84 °C. S293: (g/L ± SE, H2O) = 29.8 ± 2.7. 1H NMR (400 MHz, CD3OD-d4):
δH(ppm) = 0.13 (9H, s, H-1), 0.57-0.65 (1H, m, H-2), 0.70-0.78 (1H, m, H-2), 1.75
(15H, d, 4JH−P = 2.6 Hz, H-21), 1.88-1.97 (1H, m, H-3), 2.13-2.22 (1H, m, H-3), 3.65-
3.72 (1H, m, H-4), 4.16-4.22 (3H, m, H-4 and H-20), 4.29-4.33 (1H, m, H-20), 4.49-4.57
(5H, m, H-16 and H-19 and H-20), 4.62-4.65 (1H, m, H-18), 4.79-4.82 (1H, m, H-18),
5.05-5.08 (1H, m, H-17), 5.27-5.35 (3H, m, H-17), 6.71-6.75 (2H, m, H-7 and H-9), 7.35-
7.43 (6H, m, H-8 and H-10 and H-13 and H-14), 7.46-7.51 (1H, m, H-12), 8.17 (1H,
s, H-5). 13C{1H} NMR (100 MHz, CD3OD-d4): δC(ppm) = -1.47 (C-1), 9.66
(C-21), 14.50 (C-2), 26.71 (C-3), 46.04 (d, 1JC−P = 19.8 Hz, C-19), 47.08 (d, 1JC−P
= 18.3 Hz, C-20), 49.36 (d, 1JC−P = 18.3 Hz, C-20), 66.20 (C-16), 70.81 (d, 3JC−P =
6.6 Hz, C-18), 73.58 (C-4), 80.44 (d, 3JC−P = 4.4 Hz, C-17), 81.07 (d, 3JC−P = 4.4
Hz, C-17), 96.56 (d, 2JC−P = 2.9 Hz, C-22), 118.77 (C-9), 123.41 (C-6), 123.50 (C-7),
126.19 (C-15), 130.62 (C-13), 132.05 (C-14), 134.08 (C-12), 136.41 (C-10), 136.97 (C-8),
163.33 (C-11), 165.57 (C-5). 31P{1H} NMR (162 MHz, CD3OD-d4): δP (ppm)
= -42.27 (s). IR (ATR): νmax/cm
−1 = 1607 (C=N). ESI-MS (HR) m/z 845.3151
(100%, [M-Cl]+ requires 845.3115). Analysis Calc. C36H54Cl2IrN4OPSi · 3 H2O:
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C, 46.24; H, 6.47; N, 5.99. Found: C, 46.18; H, 6.17; N, 5.93.
6.5.1.9 Ruthenium ferrocenyl PTA complex (3.13)
3.1 (0.0216 g, 0.0761 mmol) was reacted with 2.14 (0.0428 g, 0.0711 mmol). Com-
plex 3.13 was isolated as a red powder. Yield: 0.0144 g (22.9 %). 1H NMR (400
MHz, CD3OD-d4): δH(ppm) = 1.12 (3H, d,
3J = 6.8 Hz, H-22), 1.19 (3H, d, 3J
= 6.8 Hz, H-22), 2.00 (3H, s, H-28), 2.50 (1H, sept, 3J = 6.8 Hz, H-23), 4.14-4.18
(2H, m, H-21), 4.26-4.42 (11H, m, H-1, H-17, H-20 and H-21), 4.57-4.60 (2H, m, H-2
and H-19), 4.68-4.70 (2H, m, H-3), 4.84-4.91 (2H, m, H-2 and H-19), 5.14-5.28 (4H,
m, H-18), 5.80-5.83 (2H, m, H-25 and H-26), 6.31 (1H, d, 3J = 5.9 Hz, H-25), 6.42
(1H, d, 3J = 5.1 Hz, H-26), 6.71-6.77 (2H, m, H-8 and H-10), 7.32-7.38 (4H, m, H-
9, H-11 and H-15), 7.42-7.46 (2H, t, 3J = 7.5 Hz, H-14), 7.53-7.61 (1H, m, H-13),
7.93 (1H, d, 3J = 2.0 Hz, H-6), 8.51 (1H, s, H-5). 13C{1H} NMR (100 MHz,
CD3OD-d4): δC(ppm) = 18.47 (C-28), 22.10 (C-22), 22.69 (C-22), 32.19 (C-23),
49.41 (d, 1JC−P = 23.1 Hz, C-21), 50.06 (d, 1JC−P = 16.1 Hz, C-20), 51.97 (d, 1JC−P
= 11.0 Hz, C-21), 66.67 (C-17), 69.78 (C-2), 71.00 (C-1), 71.54 (C-19), 73.54 (C-3),
73.72 (C-3), 76.97 (C-4), 80.89 (m, C-18), 81.19 (C-18), 88.27 (C-25), 88.40 (C-26),
92.15 (C-26), 93.83 (C-25), 104.00 (C-27), 117.12 (C-24), 117.95 (C-10), 121.08 (C-7),
123.66 (C-8), 126.15 (C-16), 130.82 (C-14), 132.19 (C-13), 134.13 (C-15), 136.25 (C-
11), 136.90 (C-9), 157.03 (C-6), 161.26 (C-5), 165.65 (C-12). 31P{1H} NMR (162
MHz, CD3OD-d4): δP (ppm) = -11.94 (s). IR (ATR): νmax/cm
−1 = 1599 (C=N).
ESI-MS (HR) m/z 567.0771 (40%, [M-Cl-C13H19ClN3P]
+ requires 567.0673). Anal-
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ysis Calc. C41H48Cl2FeN5OPRu · 4 H2O: C, 51.42; H, 5.89; N, 7.31. Found: C,
51.91; H, 5.75; N, 7.20.
6.5.1.10 Rhodium ferrocenylimine PTA complex (3.14)
Silver hexafluorophosphate (0.0470 g, 0.185 mmol), 2.15 (0.0419 g, 0.0693 mmol) and
3.1 (0.0247 g, 0.0870 mmol) were reacted. Compound 3.14 was isolated as a red
powder. Yield: 0.0194 g (25.3 %). Melting Point: 175°C to dec. with melting. 1H
NMR (400 MHz, CD3OD-d4): δH(ppm) = 1.69 (15H, d,
4JH−P = 3.9 Hz, H-22),
3.89-3.94 (1H, m, H-21), 4.01-4.10 (3H, m, H-21), 4.21-4.23 (2H, m, H-17), 4.39 (5H,
s, H-1), 4.55-4.59 (2H, m, H-20), 4.71-4.72 (2H, m, H-2), 4.77-4.79 (1H, m, H-19),
4.84-4.86 (2H, m, H-3), 4.92-5.01 (2H, m, H-18 and H-19), 5.13-5.21 (3H, m, H-18),
6.77-6.81 (1H, m, H-10), 6.86-6.90 (1H, m, H-8), 7.22-7.26 (1H, m, H-11), 7.40-7.46
(4H, m, H-14 and H-15), 7.50-7.56 (2H, m, H-9 and H-13), 8.31 (1H, s, H-5), 8.34
(1H, s, H-6). 31P{1H} NMR (162 MHz, CD3OD-d4) : δP (ppm) = -144.43 (2P,
sept, 1JP−F = 710.1 Hz, PF6), -23.09 (1P, d,
1JP−Rh = 150.6 Hz, P(CH2N)3). IR
(ATR): νmax/cm
−1 = 1600 (C=N). ESI-MS (HR) m/z 569.0773 (100%, [M-2PF6-
C13H19N3P]
+ requires 569.0757). Analysis Calc. C41H49F12FeN5OP3Rh · 5 H2O:
C, 41.12; H, 4.97; N, 5.85. Found: C, 41.02; H, 3.50; N, 5.84.
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6.5.1.11 Iridium ferrocenylimine PTA complex (3.15)
Silver hexafluorophosphate (0.0440 g, 0.173 mmol), 2.16 (0.0391 g, 0.0563 mmol) and
3.1 (0.0181 g, 0.0637 mmol) were reacted. Compound 3.15 was isolated as a red
powder. Yield: 0.0243 g (36.1 %). Melting Point: 180°C– dec. with melting. 1H
NMR (400 MHz, CD3OD-d4): δH(ppm) = 1.71 (15H, d,
4JH−P = 2.58 Hz, H-
22), 3.98-4.11 (4H, m, H-17 and H-21), 4.18-4.26 (2H, m, H-21), 4.37 (5H, s, H-1),
4.52-4.59 (3H, m, H-19 and H-20), 4.69-4.70 (2H, m, H-2), 4.80-4.82 (2H, m, H-3),
4.86-4.90 (1H, m, H-19), 4.94-5.00 (2H, m, H-18), 5.12-5.22 (2H, m, H-18), 6.74-6.79
(1H, m, H-10), 6.82-6.85 (1H, m, H-8), 7.22-7.26 (1H, m, H-11), 7.37-7.54 (6H, m,
H-9 and H-13 and H-14 and H-15), 8.31 (1H, s, H-5), 8.34 (1H, s, H-6). 31P{1H}
NMR (162 MHz, CD3OD-d4): δP (ppm) = -144.43 (2P, sept,
1JP−F = 710.1
Hz, PF6), -42.36 (1P, s, P(CH2N)3). IR (ATR): νmax/cm
−1 = 1601 (C=N). ESI-
MS (HR) m/z 659.1287 (40%, [M-2PF6-C13H19N3P]
+ requires 659.1331). Analysis
Calc. C41H49F12FeIrN5OP3 ·CH2Cl2: C, 39.36; H, 4.01; N, 5.46. Found: C, 39.00;
H, 3.29; N, 5.91.
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6.6 Single Crystal X-ray Analysis
Single crystal X-ray diffraction data were collected on a Bruker KAPPA APEX II
DUO diffractometer using graphite-monochromated Mo-Kα radiation (λ = 0.71073
A˚). The temperature was controlled using an Oxford Cryostream cooling system (Ox-
ford Cryostat). Data scaling and absorption correction were performed using SAINT9
and SADABS.10 Structures were solved by direct methods using SHELXS-9710 and
refined by full-matrix least-squares methods based on F 2 using SHELXL-2014 with X-
Seed11,12 used as the graphical interface. X-Seed and POV-Ray were used to prepare
molecular graphic images. The crystallographic data for complexes 2.8-2.10 and 3.8
are presented on Table 2.3 (page 47) and Table 3.3 (page 66), respectively. All crystals
were isolated as red blocks from deuterated methanol in an NMR tube.
6.7 Cyclic Voltammetry Studies
Cyclic voltammetry studies were conducted using a Bioanalytical Systems Inc. BAS100W
Electrochemical Analyser with a one-compartment, three electrode system comprising
of a platinum disk working electrode, a platinum wire auxiliary electrode and a Ag/Ag+
reference electrode (0.01 M AgNO3 and 0.1 M [n-Bu4N][ClO4] in anhydrous acetroni-
trile). The reported E values (see Table 3.4) are with reference to this electrode. All
measurements were made on anhydrous acetonitrile solutions which were 2-4 mM in
sample and contained 0.1 M [n-Bu4N][ClO4] as background electrolyte, and performed
at ambient temperature. IR compensation was employed for all measurements. Un-
less stated otherwise, the scan rate used was 100 mV/s. Under these conditions, the
Fc/Fc+ couple, which was used as a reference, had an E1/2 value of +0.10 V and ∆Ep
= 100 mV. All solutions were purged with argon and voltammograms were recorded
under a blanket of argon. The platinum disk working electrode was polished between
runs.
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6.8 In vitro Cytotoxicity
Cells (MCF7) were seeded in a 96-well plate (5000 cells per well) and after 48 hours
they were treated with vehicle (1.0 µM DMSO) or complexes 2.5-2.16 and 3.1-3.15
at 20 µM for 48 hours. Cell viability of these complexes was assessed using 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, as described in
the literature.13 The absorbance at 550 nm was determined for each well using a spec-
trophotometer (RTQ2100C Microplate Reader, Ryto, China) and normalised to the
RPMI medium absorbance. This experiment was performed three times in quadru-
plicate, and then the mean cell viability determined using GraphPad Prism version
5.0. For IC50 (concentration required for 50% viability) determination of 2.8, 2.10
and 2.13, cells were treated using concentrations of 5-25 µM on three occasions in
quadruplicate. For the Chinese hamster ovarian (CHO) cells, 3000 cells per well were
plated and tested at concentrations of 0.001, 0.01, 0.1, 1, 10 and 100 µg/mL.
6.9 Aqueous Stability and GMP Binding Study
The stability of complexes 2.8 and 2.10 was investigated by 1H NMR experiments in
which approximately 3.0 mg of the complex was dissolved in 0.5 mL DMSO-d6, 0.5
mL of 50% H2O in DMSO-d6 (by volume) or 150 mM NaCl solution in 0.5 mL of 50%
H2O in DMSO-d6 (by volume). The NMR samples were heated and maintained at
37 °C between sampling. 1H NMR spectra were collected at 0, 24 and 48 hours after
the initial sample preparation. Similarly, approximately 3.0 mg of sodium 5′-guanosine
monophoshate was dissolved in 0.25 mL H2O, and mixed with 3.0 mg of complex in
0.25 mL DMSO-d6. The sample was monitored at 0, 24 and 48 hours after preparation
while heated to 37 °C between NMR sampling.
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